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1. INTRODUCTION
Cardiovascular   diseases   account   for  a   large  proportion  of   all   deaths   and  disability
worldwide. Global Burden of Disease (GBD) Study reported that there were 5.2 million  deaths
from cardiovascular diseases in economically developed countries and 9.1 million  deaths from
the same causes in developing countries . Worldwide prevalence estimates for hypertension may
be as much as 1 billion individuals, and approximately 7.1 million deaths  per  year  may  be
attributable  to  hypertension 44.  Hypertension  is  directly responsible for 57% of all stroke
deaths  and  24%  of  all  coronary  heart  disease  deaths  in  India.   Pooling   of   Indian
epidemiological  studies  shows  that  hypertension  is  present  in 25%  urban  and  10%  rural
subjects.  Therefore  cost  effective  approaches  to  optimally control blood pressure among
Indians are very much needed. Although novel drug-delivery systems have been used in other
areas of medicine, their application in  the  treatment  of  hypertension  has  been  relatively
recent1.
        Oral drug delivery has been known for decades as the most widely utilized route of
administration among all the routes that have been explode for systematic delivery of drug
via various pharmaceutical products of different dosage form. Popularity of oral route may
be ease of administration as well as traditional belief that by oral administration the drug is
well  adsorbed  as  food  stuff  ingested  daily2.
         In recent times, various developed and developing countries move towards
combination therapy for treatment of multiple diseases and disorders requiring long term
therapy such as hypertension and diabetes. Combination therapy have various advantages
over monotherapy such as problem of dose dependent side effects is minimized, a low
dose combination of two different agents reduces the dose related risk, the addition of one
agent may potentiate effects of other agent. 
Using low dosage of two different agents minimizes the clinical and metabolic side
effects that occur with maximal dosage of individual component of the combined tablet and
thus dose  of the single components can be reduced. Bilayer tablets are novel drug
delivery systems where combination of two or more drugs in a single unit having different
release profiles improves patient compliance, prolongs the drugs action, avoid saw  tooth
kinetics resulting in effective therapy along with better control of plasma drug level.
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Bilayer tablet are very common dosage form for drugs such as captopril, metoprolol,
amoxicillin and potassium clavuanate, propranolol hydrochloride,  bambuterol
hydrochloride. Joint National Committee VI recognized the value of combination
therapy and suggested that combining drug with different modes of action will often
allow smaller doses of drugs to be used to achieve control and minimize the potential
dose dependent side effects.
JNC VI recommended that the  combination of a low dose of two drugs in fixed dose
combination is an appropriate choice for initial treatment of any chronic disease. Hence
management of multiple  diseases  can  be  effectively and  better  done  by bilayer  tablet  or
layering in tablet.
Lay  ere  d tablet3,4: 
Layer tablet are composed of two or three layers of granulation compressed
together. They have appearance like as sandwich because the edges of each layer are exposed.
This dosage form has the advantage of separating two incompatible  substances with
an inert barrier between them. Layer tablet may be bilayer, trilayer or multilayer depending
upon the number of layer.
Multilayer tablets:
              This tablet consists of two or more layers of materials compressed
successively in the same tablets. The colour of each layer may be the same or different.
The tablets having layers of different colour are known multicoloured tablets. 
Multilayer tablets are tablets made by compressing several different
granulations fed into a die in succession, one on top of another, in layers. Each layer comes
from a separate feed frame with individual weight control. Rotary tablet presses can be
set up for two or three layer. More are possible but the design becomes very special. Ideally, a
slight compression of each layer and individual layer ejection permits  weight  checking for
control purposes.
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Advantage of multilayer tablets:
• This dosage form has the advantage of separating two incompatible substances with
an inert barrier between them
• It makes possible sustained-release preparations with the immediate-release
quantity in one layer and the slow release proportion in the second. A third layer,
with an immediate release might be added.
• The weight of each layer can be accurately controlled, in contrast to putting one
drug of a combination product in a sugar coating. 
• Two-layer tablets require fewer materials than compression coated tablets,weigh
less, and may be thinner.
• Monograms and other distinctive markings may be impressed in the surface of  the
multilayer tablets. 
• Colouring the separate layer provides many possibilities for unique tablet
identity.
• Analytical work may be simplified by the separation of layer prior to assay.
• Since there is no transfer to a second set of punches and dies, as with the dry
coating machine, odd shapes ( such as triangle, squares, and ovals ) present no
operating problems except for those common to keyed tooling.
      Problems in layered tablets:
• Lack of proper bonding of two layers 
• Stress due to high compression force degrades certain actives e.g ramipril.
Bilayer tablets: 
• Pharmaceutical tablet manufacturers have long sought to define and optimize the
process utilized for producing double-layer tables. Whether driven by capacity
requirements, marketing-based ideas or simple physics, there are always unique
factors to be considered when developing a standard procedure for a repeatable
manufacturing process. The creation of one solid dosage form, in particular, has long
been thought of as a process that could be more accurately described as an art form.
• Double- layer (or bi-layer) tablets have been around for recentime.
Quitepossibly the earliest uses of this dosage form were driven form a
marketing perspective, with emphasis placed on the perception of the consumer
who would be utilizing the product. A tablet with two mutually exclusive ―layers
represented by two clearly different colours, provided manufacturers with a way to
produce a product that looked more interesting than a standard white ―pill. While
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this motivation still  has its place in modern pharmaceutical manufacturing the
double-layer dosage form has evolved into much more than a product with purely
visual appeal. Some double-layer products are ultimately coated, anyway, with the
final form appearing to be comprised of one uniform substance.
Potential Reason for Considering the Double-layer Dosage Form: 
 One of the more common reasons that have developed for wishing to
manufacture double-layer product centers on sustained release versus  immediate
release active ingredients and the related bioavailability of each  within the human body. It
is the intention of the manufacturer in some cases  to formulate products that utilize
two different actives, one whose pharmacological effect is available to the body shortly
after it is ingested  (immediate release) and another that fulfills its role more slowly over a
longer   period of time (sustained release). These two functions can be neatly
delivered in the same tablet by separating the actives into two distinct layers.
Some active ingredient combinations for a tablet may also be better suited   to the double-
layer form if they cannot easily be blended into the same final  formulation.  Certain
ingredient may simply need to be physically separated  due to incompatibility. An example of
a characteristic that might foster such incompatibility would be disparate dissolution rates.
• Another modern catalyst for utilization of the double-layer form focuses on the idea
of product line extension. As patent protection begins to wane   manufactures can
sometimes breathe a new life into a product line by  modifying its format or
presentation. This can in some cases be achieved by creating a double-layer version of what
was historically in mono-layer tablet. The best cases may result in a new patent for the
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revised form, thereby extending the life of a product line. 
• Perhaps the most interesting emerging use for a double-layer tablet focuses on  the
desire to thwart abuse of a constituent ingredient. Abusers of  pharmaceutical
preparation  have  been  increasingly  successful  and  inventive  in   their ability to extract
powerful ingredient for use not intended by the manufacturer.
Some novel bilayer and trilayer tablet devices
A. Sustained release bilayer tablets: 
The multilayered tablet concept has been long utilized to develop sustained  release
formulations. Such a tablet has a fast releasing layer and may contain bi- or triple layers to
sustained the drug release. The pharmacokinetic advantage relies on the fact that drug
release from fast releasing granules lead to a sudden rise in the  blood concentration.
However, the blood level is maintained at steady state as the drug is released from the
sustaining granule. Among the different polymers, Eudragit and ethylcellulose have been used
successfully to obtain appropriate sustained release matrix formulations of different materials5.
B. Bilayer and floating-bioadhesive tablets: 
A bilayer and floating-bioadhesive drug delivery system exhibiting a unique
combination of floatation and bioadhesion to prolong residence in the stomach. The
sustained layer was compressed and granules of the floating layer were added to it then
both layers were compressed using a single station rotator press. Granules and tablets were
characterized using a official method. The kind of the tablet exhibits  independent
regulation of buoyancy and drug release6.
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C. Bilayer caplets:
A bilayer caplets are excellent in two respect; firstly, single unit, such as bilayer caplets,
excel in unit size than multiple unit, such as spansule capsules, and secondly, tablet shape
changes  from  flat  to  capsule-like,  namely caplets,  that  improves  easiness  in  swallowing as
compared with flat tablets7.
D. Tablet in capsule devices:
This novel system is so-called ―tablet in capsule devices. The designed capsule  device
consists  of an  impermeable capsule body and a soluble cap.  The multi-layered formulation
prepared is filled within the capsule body and sealed with the water-soluble cap. Three-
layered tablets, which serves as the first two pulses, a two-layered tablet or in powdered
forms, which forms the third pulsatile drug release. Both multi-layer tables are inserted into
an impermeable capsule body with a water-soluble cap, lactose filled in the bottom8.
E. Three layered tablet system:
To allow biphasic drug release a three-layer tablet system has been developed. Two layers both
contain a drug dose. An outer drug layer contains the immediately available dose of drug. An
intermediate, made of swellable polymers, separates the  drug layers. A film of an
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impermeable polymer coats the layer containing the other dose of drug. The first layer can
also involve a drug-free hydrophilic polymer barrier providing delayed (5h) drug absorption9.
Bilayer problems10: 
• Layer-separation. 
• Insufficient hardness. 
• Inaccurate individual layer weight control.
• Cross contamination between the layers. 
     • Reduced yield.
Bi-Layer tablets: Quality and GMP-requirement10: 
To produce a quality bi-layer tablet, in a validated and GMP-way, it is important
that the selected press is capable of- 
• Preventing capping and separation of the two individual layers that constitute the bi-
layer tablet.
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• Providing sufficient tablet hardness. 
• Preventing cross-contamination between the two layers.
• Producing a clear visual separation between the two layers. 
• High yield.
• Accurate and individual weight control of the two layers. 
Sustained Release Drug Delivery Systems:
Sustained release, sustained action, prolonged action, controlled release, extended action,
timed release, depot, and repository dosage forms, are terms used to identify drug delivery
systems that are designed to achieve a prolonged therapeutic  effect by continuously
releasing medication over an extended period of time after administration of a single dose.
In the case of injectables dosage forms, these period may vary from days to months. In the
case of orally administrated forms, however, these periods is measured in hours and critically
depends on the residence time of the dosage form in the gastrointestinal tract. The term
―controlled release has became  associated with those systems, from which therapeutic
agents may be automatically delivered at predefined rates over a long period of time11.
Design and Fabrication of Oral Sustained Release Drug Delivery System12:
The oral route of administration is the most preferred route due to flexibility in dosage form,
design and patient compliance. But here one has to take consideration, the various pH
that the dosage form would encounter during its transit, gastrointestinal motility,
the enzyme system and its influence on the drug and the dosage form. The majority of
oral sustained release systems rely on dissolution,  diffusion or a combination of both
mechanisms, to generate slow release of drug to the gastrointestinal milieu. Theoretically
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and desirably a sustained release delivery device, should release the drug by zero order
process which would result in a blood level  time  profile  similar  to  that  after  intravenous
constant rate infusion
V
Fig-1: Plasma drug concentrations-profiles for conventional tablet or capsule
formulation, a sustained release formulation, and a zero-order controlled release
formulation.
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Fig-2: Comparison of conventional and controlled release profiles
Fig-3: Dosage Regiem for conventional and controlled release systems
Sustained drug release has been attempted to be achieved, by following classes 
of sustained drug delivery system. 
A) Diffusion sustained system.
i) Reservoir type.
ii) Matrix type
B) Dissolution sustained system. 
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i) Reservoir type.
ii) Matrix type
C) Methods using Ion-exchange. 
D) Methods using osmotic pressure.
E) pH independent formulations.
F) Altered density formulations.
A] Diffusion sustained system:
Basically diffusion process shows the movement of drug molecules from a region of
a higher concentration to one of lower concentration. The flux of the drug J(in amount /
area -time), across a membrane in the direction of decreasing 
concentration is given by Fick‘s law. 
J= - D dc/dx.
D = diffusion coefficient in area/ time
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dc/dx = change of concentration 'c' with distance 'x' 
In common form, when a water insoluble membrane encloses a core of drug, it must diffuse
through the membrane, the drug release rate dm/ dt is given by,
dm/ dt= ADKD C/L 
Where A = area 
K = Partition coefficient of drug between the membrane and drug core
L= diffusion path length [i.e. thickness of coat]
Dc= concentration difference across the membrane.
1] Reservoir t  y  pe:
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Fig-4: Schematic representation of diffusion sustained drug release: reservoir System
In the system, a water insoluble polymeric material encases a core of drug.  Drug will
partition into the membrane and exchange with the fluid surrounding the particle or tablet.
Additional drug will enter the polymer, diffuse to the periphery and  exchange  with  the
surrounding media.
Characteriza  t  ion
Description: Drug core surrounded by polymer membrane which controls release rate.
Advantages: Zero order delivery is possible, release rates variable with polymer type.
ii] Matrix t  y  pe:
A solid drug is dispersed in an insoluble matrix and the rate of release of drug is
dependent on the rate of drug diffusion and not on the rate of solid dissolution.  Higuchi has
derived the appropriate equation for drug release for this system, 
                Q = De/ T [2 A –eCs] Cst ½
Where; 
Q = weight in gms of drug released per unit area of surface at time t
D = Diffusion coefficient of drug in the release medium 
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e = porosity of the matrix 
Cs = solubility of drug in release medium
T= Tortuosity of the matrix 
A = concentration of drug in the tablet, as gm/ ml
Characterization 
Description: Homogenous dispersion of solid drug in a polymer mixture.
Fig-5: Schematic representation of diffusion sustained drug release: matrix
system
A third possible diffusion mechanism is the system where a partially soluble
membrane encloses a drug core. Dissolution of part of membrane allows for diffusion of the
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constrained drug through pores in the polymer coat. The release rate can be given by following
equation:-
Release rate = AD / L = [ C1- C2 ]
Where, A = Area,
D = diffusion coefficient,
C1 = Drug concentration in the core, 
C2 = Drug concentration in the surrounding medium, 
L = diffusional path length
Thus diffusion sustained products are based on two approaches the first
approach entails placement of the drug in an insoluble matrix of some sort. The eluting
medium penetrates the matrix and drug diffuses out of the matrix to the surrounding
pool for ultimate absorption. The second approach involves enclosing the drug particle with a
polymer coat. In this case the portion of the drug which has dissolved in the polymer coat
diffuses through an unstirred film of liquid into the surrounding fluid.
B] Dissolution sustained systems:
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A drug with a slow dissolution rate is inherently sustained and for those drugs with
high water solubility, one can decrease dissolution through appropriate salt or derivative
formation. These systems are most commonly employed in the production of enteric coated
dosage forms. To protect the stomach from the effects of drugs such as Aspirin, a coating that
dissolves in natural or alkaline media is used. This inhibits release of drug from the device
until it reaches the higher pH of the intestine. In most cases, enteric coated dosage forms are
not truly sustaining in nature, but serve as a useful function in directing release of the drug to
a special site.
i) Reservoir t  y  pe:
Drug is coated with a given thickness coating, which is slowly dissolved in the contents
of gastrointestinal tract. By alternating layers of drug with the rate controlling coats
as shown in figure, a pulsed delivery can be achieved. If the outer layer is quickly releasing
bolus dose of the drug, initial levels of the drug in the body can be quickly established with
pulsed intervals. An alternative method is to administer the drug as group of beads that
have coating of different thickness. This is  shown in figure. Since the beads have different
coating thickness, their release occurs in a progressive manner. Those with the thinnest layers
will provide the initial dose. The maintenance of drug levels at late times will be achieved from
those with thicker coating.
i) Matrix t  y  pe:
The more common type of dissolution from sustained dosage form as shown in figure.
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It can be either a drug impregnated sphere or a drug impregnated tablet, which will  be
subjected to slow erosion.
Two types of dissolution- sustained pulsed delivery systems:
a] Single bead– type device with alternating drug and rate-controlling layer. 
b] Beads containing drug with differing thickness of dissolving coats
C] Methods using lon Exchange:
It is based on the formation of drug resin complex formed when a ionic solution
is kept in contact with ionic resins. The drug from these complex gets exchanged in
gastrointestinal tract and released with excess of Na+ and Cl- present in gastrointestinal tract
Resin + - Drug - + Cl- goes to resin + Cl- + Drug- 
Where x- is cl- conversely
Resin - - drug+ + Na +goes resin – Na+ + Drug.
D] Methods using osmotic pressure: 
A semi permeable membrane is placed around a tablet, particle or drug solution
that allows transport of water into the tablet with eventual pumping of drug solution out of
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the tablet through a small delivery aperture in tablet coating.
Two types of osmotically sustained systems are:-
Type A contains an osmotic core with drug
Type B contains the drug in flexible bag with osmotic core surrounding.
E] pH– Independent formulations:
The gastrointestinal tract present some unusual features for the oral route of drug
administration with relatively brief transit time through the gastrointestinal tract, which
constraint the length of prolongation, further the chemical environment throughout the
length of gastrointestinal tract is constraint on dosage form design.  Since most drugs are
either weak acids or weak bases, the release from sustained release formulations is pH
dependent. However, buffers such as salts of amino acids,  citric acid, phthalic acid
phosphoric acid or tartaric acid can be added to the formulation, to help to maintain a
constant pH  thereby rendering pH independent drug release. A buffered sustained release
formulation is prepared by mixing a basic or acidic drug with one or more buffering
agent, granulating with appropriate pharmaceutical excipients and coating with
gastrointestinal fluid permeable film  forming polymer. When gastrointestinal fluid
permeates through the membrane, the buffering agents adjust the fluid inside to suitable
constant pH thereby rendering a constant rate of drug release e.g. propoxyphene in a
buffered sustained release formulation, which significantly increase reproducibility.
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F] Altered density formulations: 
Several approaches have been developed to prolong the residence time of drug delivery
system in the gastrointestinal tract. 
High density approach:
In this approach the density of the pellets must exceed that of normal stomach content and
should therefore be at least 1-4gm/cm3.
Low density approach:
Globular shells which have an apparent density lower than that of gastric fluid can be used as a
carrier of drug for sustained release purpose.
Drug release mechanism from sustained release tablet13: 
1. Zero-order release kinetics (Lazarus and Cooper, 1961) 
Q(t) =k0t
Where Q(t) is the percent of drug dissolved as a function of time ‗t‘ in minutes
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and k0 describes the dissolution rate constant for zero-order release. A plot of the percent of
drug released against time will be linear if the release obeys zero-order  release kinetics.
Values of release rate constant k0 were obtained in each case from the slope of percent drug
released versus time plots.
2. First-order release kinetics (Gibaldi and Feldman, 1967, Wagner, 1969)
                                      
                              log Qt = log Q0+ k1t∕2.303
The first-order equation describes the release from systems where release rate  is
concentration dependent. Where Q0 is the initial amount of the drug, ‗t‘ is in minutes
and k1 describes the dissolution rate constant for first-order release kinetics. A plot of the
logarithm of the percent drug remained against time will be linear if the release obeys first-
order release kinetics.Values of release rate constant kt were obtained in each case from
the slope of the log percent drug remained versus time plots.
3. The simplified Higuchi model (Higuchi, 1961 and 1963)
Q(t) = k H t
1/ 2
Where Q(t) is the percent of drug dissolved, time ‗t‘ in minutes, kH is a
dissolution rate constant for square root of time kinetics in percent dissolved min–½.A plot of
the fraction of drug released against square root of time will be linear if the release obeys
Higuchi equation. Values of release of rate constant kH were obtained in each case from the
slope of the percent drug released versus square root of time plots.
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4. The Fickian and non-Fickian drug release model (Korsmeyer et al, 1983)
In order to define a model, which will represent a better fit for the release from the
tablet formulations, dissolution data up to 60% can be further analyzed using Peppas and
Korsmeyer equation (power law). To evaluate the contribution of the release mechanisms
other than diffusion, other models of the release kinetics were employed. Since erosion of
the matrix will contribute to the release, a model describing general solute release from
hydrophilic polymers as employed by the Korsmeyer et al (1983) was used. Applied to
the hydrophilic polymers it has the simplified empirical form (Ford et al, 1991).
      Equation.
     
Where k is the release rate and n is the release exponent. Values of the release exponent
(n) and the kinetic constant (k) obtained in each case from the slope and y-intercept of a
logarithmic plot of percent released versus time respectively. Peppas (1985) used this n
value in order to characterize different release mechanisms.
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REVIEW OF LITERATURE  
 3. REVIEW OF LITERATURE
                     Literature survey on formulation and evaluation of bilayer matrix tablet  was
carried out by referring various scientific journals, internet and helinet facility. A survey
of  literature  reveals  that  extensive  work  was  conducted  employing  hydrphylic  and
hydrophobic polymer to prepare matrix tablet.
•  The present work aims to investing the possibility of sustaining the Losartan
potassium release from matrix tablet, prepared by hydrophilic and hydrophobic
polymer. The mechanism of drug release was diffusion coupled with erosion. It
can be concluded that the polymer plays a major role in the design of sustained
release matrix tablet. The study reveals that the release of drug is low when the
matrix tablet contained hydrophilic and hydrophobic polymers as a combination
than  the  other  matrices  and  also  shows  anomalous(non-fickian)  diffusion
kinetics. Hence, it is clearly manifest the necessity of combining different classes
of polymer is to get an acceptable pharmacokinetic profile in the fluctuating in
vivo environment14 .
• The  present  study  was  to  develop  hydrophilic  polymer  and  hydrophobic
polymer based matrix Losartan potassium sustained release tablet which can
release the  drug up to  time  of  24 hrs  in predetermined rate.  Formulation of
Losartan potassium matrix tablet was prepared by the polymer combination in
order to  get  required theoretical  release profile.  Influence of  hydrophilic  and
hydrophobic polymer on Losartan potassium was studied. Administration of LP
in  a  sustained  release  dosage  would  be  more  desirable  for  antihypertensive
effects  by  maintaining the  plasma concentrations  of  the drug well  above the
therapeutic concentration.(polymer)15
26
REVIEW OF LITERATURE  
•  The present study was to develop a sustained release matrix tablets of Losartan
potassium,  an  anti  hypertensive  drug.  The  sustained  release  tablets  were
prepared  by  wet  granulation.A decrease  in  release  kinetics  of  the  drug  was
observed  on increasing polymer  ratio.  Applying exponential  equation,  all  the
formulation tablets(except F3) showed diffusion-dominated drug release.  The
mechanism of drug release from F3 was diffusion coupled with erosion.(polymer
n release mec)16
• In  the  present  research,  an  attempt  has  been  made  to  formulate  sustained
release matrix tablet of nicorandil,  a  novel potassium channel opener used in
cardiovascular disease. The tablets were prepared by wet granulation method
and studied the effect of matrix former xanthan gum and guar gum separately.
Tablets  were  evaluated  for  uniformity  of  weight,  drug  content,  friability,
hardness,  thickness,  in  vitro  dissolution  and  swelling  study.  The  dissolution
result  shows that  an increased amount of  polymer resulted in retarded drug
release17.
• The present  research work  on  bilayer  tablet  is  new  era  for  the  successful
development of  controlled release formulation along with various features  to
provide a way of successful drug delivery system. Bilayer tablet is better than the
traditionally  used mouthwash,  sprays,  gels.  So use of  bilayer  tablet  is  a  very
different aspect for anti-inflammatory and analgesic.  Bi-layer tablet is suitable
for sequential release of two drugs in combination, separate two incompatible
substances and also for sustained release tablet in which one Layer is immediate
release as initial dose and second layer is maintenance dose.  Bilayer tablet is
improved  beneficial  technology  to  overcome  the  shortcoming  of  the  single
layered tablet19.
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REVIEW OF LITERATURE  
• The emerging new  work on fixed dose combination of Metformin Hydrochloride
(HCl) as sustained release and Glipizide as immediate release were formulated
as a bilayer matrix tablet. Three different grades of (HPMC K 4M, HPMC K15M,
HPMC  K100M)  were  used.  In  vitro  release  studies  were  carried  out  with  a
phosphate buffer of pH 6.8 using USP dissolution apparatus 2 (paddle). Tablet
thus formulated using HPMC K100M provided sustained release of Metformin
HCl over a period of 10 hours.  In-vitro  release studies were carried out with a
phosphate buffer of pH 6.8 using USP dissolution apparatus 2 (paddle). Tablet
thus formulated using drug and carrier at 1:8 ratio provided immediate release
of Glipizide over a period of 10 minutes20.
• The  present study  was  to  prepare  bi-layer  tablet  of  Metoclopramide
Hydrochloride (MTH) and Ibuprofen (IB) for the effective treatment of migraine.
MTH  and  IB  were  formulated  as  immediate  and  sustained  release  layer
respectively.  The  effect  of  concentration  of  hydrophilic  matrix  (HPMC  K4M),
binder (polyvinylpyrollidone [PVP K30]) and buffer (sodium bicarbonate) on IB
release was studied21.
• The objective of present investigation was to develop venlafaxine hydrochloride-
layered  tablets  for  obtaining  sustained  drug  release.  The  tablets  containing
venlafaxine hydrochloride 150 mg were prepared by wet granulation technique
using xanthan gum in the middle  layer  and barrier  layers.  The granules  and
tablets were characterized. The in vitro drug dissolution study was conducted in
distilled water. The tablets containing two lower strengths were also developed
using the same percentage composition of  the middle  layer.  Kinetics  of  drug
release was studied21.
28
REVIEW OF LITERATURE  
• The objective  of  present investigation was to  develop dual  component  tablet
made up of a sustained release and an immediate release layer was prepared by
direct  compression.  A  32  full  factorial  design  was  applied  to  systematically
optimize the drug release profile of the sustained release layer. The results of the
full factorial design indicate that a small amount of HPMC K100M and a large
amount  of  Ucarflock  302  favor  sustained  release  of  the  metoclopramide
hydrochloride vaginal dual component system22.
• The present study was to a develop bilayer sustained release tablet of Isosorbide
mononitrate,  an  anti-anginal  organic  nitrate  vasodilator.  The  tablets  were
prepared  by  wet  granulation  method.  Hydrophilic  and  hydrophobic  matrix
materials such as hydroxypropyl methylcellulose, and polyox were used, which
can release the drug up to 24hrs in predetermined rate. The formulated tablet
were  also  characterized  by  physical  and  chemical  parameters  such  as  for
granules,angle of repose, bulk density, compressibility index, total porosity, and
drug content and for the tablet thickness, hardness, diameter, weight variation
test, drug content, friability, and in vitro release studies23.
•  The  present  investigation  highlighted  the  formulation  and  optimization  of
losartan potassium tablets. To achieve this goal, various formulation of losartan
potassium  tablets  were  prepared  and  evaluated  with  respect  to  the  various
quality parameters both in process parameters for granules and parameters for
finished products . On the basis of these parameters, the formula was optimized
and compared with the innovator. It was observed that the optimized losartan
potassium  tablets  was  pharmaceutically  equivalent  with  the  innovator.  The
stability of optimized tablets at various atmospheric conditions was done and
stability parameters were satisfactory24.
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•  This work describes the development and validation of a dissolution test for 50
mg losartan potassium capsules using HPLC and UV spectrophotometry. A 24 full
factorial  design  was  carried  out  to  optimize  dissolution  conditions  and
potassium phosphate buffer, pH 6.8 as dissolution medium, basket as apparatus
at the stirring speed of 50 rpm and time of 30 min were considered adequate.
Both  dissolution  procedure  and  analytical  methods  were  validated  and  a
statistical  analysis  showed  that  there  are  no  significant  differences  between
HPLC and spectrophotometry25.
• The present study was to prepare twice daily sustained release matrix tablets of
losartan potassium using Eudragit RLPO, RSPO and Ethyl cellulose individually
and in combination of above polymers.  Sustained release matrix tablets were
developed  using  different  drug  polymer  ratios  and  prepared  by  direct
compression  method.  The  influence  different  concentrations  and  nature  of
polymer  was  studied.  Matrix  tablets  assessed  for  their  physicochemical
properties  and  invitro  drug  release  studies.  Drug-excipient  interaction  was
evaluated  by  Differential  scanning  calorimetry  and FTIR.  There  was  no  drug
excipient interaction26   
• The present study was to develop an optimised press-coated tablets of losartan
potassium  using  an  admixture  of  a  hydrophilic  polymer,
hydroxypropylmethylcellulose (HPMC) and microcrystalline cellulose (MCC) in
order to achieve a predetermined lag time for chronotherapy. The press-coated
tablets (PCT) containing losartan potassium in the inner core were prepared by
compression-coating with HPMC 100KM alone and admixed with MCC as the
outer layer in different ratios. The effect of the outer layer on the lag time of drug
release was investigated27
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•  This  investigation was  to  prepare  a  gastroretentive  drug  delivery  system  of
Losartan  Potassium.  Floating  tablets  of  Losartan  Potassium  were  prepared
employing three different grades of HPMC K100, HPMC K15M and HPMC K4M by
effervescent  technique.  The  prepared  tablets  exhibited  satisfactory  physico-
chemical characteristics. The tablet swelled radially and axially during in vitro
buoyancy studies. HPMC K100 based matrix tablets showed significantly greater
swelling indices compared with other batches28
•     The objective of  the study was to develop and evaluate controlled release
bilayer matrix tablets of losartan potassium employing xanthan gum and gum
karaya  as  a  polymers.  Controlled  release  bilayer  matrix  tablets  containing
losartan potassium were developed using different drug: polymer concentration.
Tablets  were  prepared  by  direct  compression  method.  Differential  scanning
calorimetry study revealed no chemical interaction between drug and polymers
used. In-vitro  release studies were carried out using USP XXIV type II (paddle
method) dissolution apparatus at 75 rpm by taking 900 ml of 0.1 N HCl (pH 1.2)
as dissolution medium for first 2 h and later replacing it with 900 ml pH 6.8
phosphate  buffer  solution  for  rest  of  the  time  period  at  37±0.5oC.  The
mechanism of drug release was found to be non-fickian diffusion29  
•  The aim of the current study was to design oral controlled release matrix tablets
of  losartan  potassium.  Tablets  were  prepared  by  direct  compression  and
evaluated for hardness, friability, thickness, drug content and in vitro dissolution
parameters.  Carbopol  934P  and  HPMC  K  100M  (hydroxyl  propyl  methyl
cellulose) were used as the polymers . In vitro release studies were conducted in
phosphate buffer pH 6.8 for 24 hours. The release profile of losartan potassium
from all the formulations (except F2, F3, F8 which showed first order release)
are close to zero order and follow diffusion dependent release. Irrespective of
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the polymer type and its concentration, the prepared hydrophilic matrix tablets
showed non-fickian (anomalous) release, coupled diffusion and polymer matrix
relaxation  as  the  values  of  release  exponent  (n)  are  in  between  0.584  and
0.869230.
• The  ultimate  aim  of  the  present  study  was  to  prepare  twice  daily  sustained
release  matrix  tablets  of  losartan potassium using  Eudragit  RLPO,  RSPO and
Ethyl  cellulose individually  and in combination of  above  polymers.  Sustained
release matrix tablets were developed using different drug polymer ratios and
prepared by direct compression method. The influence different concentrations
and nature of polymer was studied.In vitro release data shows individual low
polymer concentration of RLPO, RSPO sustain the drug release up to 10hrs but
combinations  with EC sustain the drug release more than 12hrs.Eudragits  in
higher polymer proportion drug release was extend up to 12hrs. Ethyl cellulose
has more retardation than Eudragits31.
• The  present  investigation  was  to  develop  and  evaluate  Atorvastatin  calcium
(ATC) & Metoprolol succinate (MP) in same dosage form, so there is no need to
take individual dosage form. The regioselective tablets were prepared by direct
compression.  Polyox WSR N-60K and HPMC K100M was used as  hydrophilic
polymers. The amount of polymer blends was optimized using 32 full factorial
design. The swellings and in-vitro release were studied. Diffusion exponents (n)
were  determined  for  all  the  formulations  (0.45-0.89),  so  predominant  drug
release mechanism is non-Fickian (anomalous) transport32.
• The ultimate aim of the present study was hydrophilic matrix formulations are
important  and  simple  technologies  that  are  used  to  manufacture  sustained
release dosage forms. Hydroxypropyl methylcellulose-based matrix tablets, with
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and without additives, were manufactured to investigate the rate of hydration,
rate of erosion, and rate and mechanism of drug release. The results revealed
that  the  rate  of  hydration  and  erosion  was  dependent  on  the  polymer
combination(s) used,  which in turn affected the rate  and mechanism of drug
release  from  these  formulations.  It  was  also  apparent  that  changes  in  the
microstructure of matrix tablets could be related to the different rates of drug
release that were observed from the test formulations33.
•  The present investigation was Poly(carboxyalkyl methacrylates) were studied as
a  cationic-drug  delivery  system,  at  pH  6.8  and  8.0.  Different  polymer/  drug
complexes were used to prepare compressed tablets. By kinetics experiments,
we have found that drug release is dependent on both the hydrophobicity of the
whole complex and the pH of the environment. Furthermore, a mechanism of
dissociation/erosion clearly describes the drug release from a complex formed
by  a  polymer  soluble  at  target  pH;  otherwise,  a  mechanism  of
dissolution/diffusion  is  depicted.  Additionally,  we  have  observed  that
hydrophilic fillers increase the drug release rate34
• The emerging new work on fixed dose combination of metformin hydrocholride
(HCl) as sustained release and glipizide as immediate release were formulated as
a bilayer matrix  tablet  using hydroxy propyl  methyl  cellulose (HPMC) as  the
matrix-forming  polymer,  and  the  tablets  were  evaluated  via  in  vitro  studies.
Three different grades of HPMC (HPMC K 4M, HPMC K 15M, and HPMC K 100M)
were  used.  All  tablet  formulations  yielded  quality matrix  preparations  with
satisfactory tableting properties. In vitro release studies were carried out at a
phosphate buffer of pH 6.8 with 0.75% sodium lauryl sulphate w/v using the
apparatus I (basket) as described in the United States Pharmacopeia (2000). The
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release kinetics  of  metformin were evaluated using the regression coefficient
analysis35
• The present examine on the release performance of two model drugs, diclofenac
sodium and furosemide, from two- and three-layer drug delivery systems using
as carriers hydrophilic swellable polymers, namely, Metolose, Polyox, Xantham
gum, and an erodible material Gantrez. All prepared formulations demonstrated
sustained release profiles.  They also indicated that  the carrier  characteristics
(particularly  swelling-expansion,  erosion-dissolution)  and  drug  solubility  in
combination with tablet structure considerably influenced the performance of
examined formulations as well as their mode and mechanisms of release36.
• The present examine on multi-drug tablets of amlodipine besylate and atenolol
were  prepared  as  either  mono-layer  (mixed  matrix)  or  bi--layer  tablets
containing  each  drug  in  a  separate  layer  by  using  similar  excipients  and
processing.  Each tablet  batch was packed in strip and blister  packs  and kept
under  accelerated temperature  and humidity  conditions.  The stability  of  two
tablet and packaging types was compared by HPLC analysis after 0, 1, 3 and 4.5
months  and expressed as  the  content  of  intact  amlodipine  and atenolol.  The
study revealed  that  the bi-layer  tablet  formulation was more stable  than the
mono-layer  type.  Further,  the  stability  was  increased  when  the  tablets  were
packed in aluminium strips as compared to PVC blisters37
•  The  objective  of  this  study  was  to  investigate  the  effect  of  lipophilic  and
hydrophilic  components   on the release of  carbamazepine from granules  and
corresponding  tablet.  Wet  granulation  followed  by  compression.The  matrix
swelling  behavior  was  investigated.  It  was  found  that  increase  in  the
concentration of HPMC results in reduction in the release rate from granules and
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achievement of zero-order is difficult from the granules. The amount of HPMC
plays a dominant role for the drug release. The release mechanism of CBZ from
matrix tablet formulations follows non-Fickian diffusion shifting to Case II by the
increase  of   HPMC  content,  indicating  significant  contribution  of  erosion.
Increasing in drug loading resulted in acceleration of the drug release and in
anomalous  controlled-release  mechanism  due  to  delayed  hydration  of  the
tablets38.
•  Each of the proposed DLTs is composed of a fast-release layer and a sustained-
release layer, anticipating rapid drug release that starts in the stomach to rapidly
alleviate  the symptoms and continues in the intestine to  maintain protracted
analgesic effect.  An amorphous,  freeze-dried inclusion complex of  lornoxicam
with  hydroxypropyl-β-cyclodextrin,  present  in  1:2  (drug/cyclodextrin)  molar
ratio,  was  employed  in  the  fast-release  layer  to  enhance  the  dissolution  of
lornoxicam in the stomach and assure rapid onset of its analgesic effect. Xanthan
gum (XG), a hydrophilic matrix-forming agent, was integrated in the sustained-
release layer to  provide appropriate  sustainment of  drug release.  The weight
ratios between the sustained-release layer and fast-release layer present in DLTs
were adjusted to reach optimal formulations39.
• The  present  work  on a  coated  matrix  tablet  formulation  has  been  used  to
develop  controlled  release  diltiazem  HCl  (DIL)  tablets.  The  developed  drug
delivery system provided prolonged drug release rates over a defined period of
time. DIL tablets prepared using dry mixing and direct compression and the core
consisted  of  hydrophilic  and  hydrophobic  polymers  such  as
hydroxypropylmethylcellulose (HPMC), Eudragits RLPO/RSPO, microcrystalline
cellulose,  and  lactose.  Tablets  were  coated  with  Eudragit  NE  30D,  and  the
influence  of  varying  the  inert  hydrophobic  polymers  and  the  amount  of  the
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coating  polymer  were  investigated.  The  release  profile  of  the  developed
formulation was described by the Higuchi model40.
• The objective of this research  work  was to  prepare and evaluate the effect of
Eudragit  RS  PO  and  Eudragit  RL  PO  polymers  on  the  physical  property  and
release  characteristics  of  carbamazepine  matrix  tablets.  Matrix  tablets
containing carbamazepine  were prepared with Eudragit® RS PO alone as the
rate-retarding polymer  and also with a combination of Eudragit® RS PO and RL
PO . The tablets were characterized   for hardness as well as for carbamazepine
release. The release data were subjected to different models in order to evaluate
their release kinetics and mechanisms41.
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4. MATERIALS AND METHODS
4.1 MATERIALS.
Sl no Material Source
1 Losartan Potassium kapl
2 Hydroxypropylmethylcellulose yarrow chemicals pvt ltd
3 Eudragit Rspo yarrow chemicals pvt ltd
4 Sodium Starch Glycolate yarrow chemicals pvt ltd
5 Magnesium stearate karnataka fine chem
6 Talc karnataka fine chem
Equipment: 
Sl  no Equipment Source
1 Uv-visible spectrophotometer Shimadzu-1700, shimadzu corporation, 
japan.
2 Electronic balance Bl-220h, shimadzu corporation, japan
3 Ph meter
4 Tablet punching machine Cip, machinaries pvt. Ltd., ahmedabad
5 Sonicator
6 Dissolution test apparatus Electrolab, tdt-08l, dissolution 
tester(usp)
7 Fourier-transformed infrared 
spectrophotometer(ftir)
Perkin elmer spectrum gx
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8 Hardness tester pfizer
9 Friability apparatus Electrolab, ed-2l(usp)
10 Disintegration apparatus Electrolab, ed-2l(usp)
11 Programmable Stability test 
chamber
Thermo lab, India  
12 Hot air oven Servewell instruments, Bangalore
4.3 DRUG PROFILE
Losartan potassium
Chemical formula: 
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2 - butyl - 4 - chloro - 1 - [ p- (o - 1 H - tetrazol - 5 - ylphenyl) benzyl] imidazole – 5 - 
methanol
Structural formula 
Empirical formula: C22H22ClKN6O
Molecular weight:  461.01
Description: White or almost white powder.
Melting point: 263-2640C.
Solubility: It is freely soluble in water and soluble in alcohols.
Half life: 2.5 hr
Drug category : anti hypertensive
Mechanism of action:     Losartan potassium is an angiotensin II receptor antagonist. It
suppresses the effects of angitensin II at its receptors, thereby blocking the 
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renninangiotensin system.The rennin-angiotensin system plays a crucial role in the 
control of blood pressure, and in particular it is felt to play crucial role in hypertension. 
Losartan has been demonstrated to be superior to previous peptide receptor 
antagonists and angiotensin converting enzyme (ACE) inhibitors because of its 
enhanced specificity, selectively, and tolerability. 
Pharmacokinetics:
Absorption 
Following oral administration, losartan is well absorbed and undergoes first-pass 
metabolism, forming an active carboxylic acid metabolite and other  inactive 
metabolites. The systemic bioavailability of losartan tablets is approximately 33%. 
Mean peak concentrations of losartan and its active metabolite are reached in 1 hour 
and in 3-4 hours, respectively
Distribution 
Both losartan and its active metabolite are 99% bound to plasma proteins, primarily 
albumin. The volume of distribution of losartan is 34 litres. 
Elimination 
Plasma clearance of losartan and its active metabolite is about 600 ml/min and 
50 ml/min, respectively. Renal clearance of losartan and its active metabolite is about 
74 ml/min and 26 ml/min, respectively. When losartan is administered orally, about 
4% of the dose is excreted unchanged in the urine, and about 6%  of the dose is 
excreted in the urine as active metabolite. The pharmacokinetics of losartan and its 
active metabolite are linear with oral losartan potassium doses up to 200 mg. 
METABOLISM
           Under go substantial first pass metabolim by cyp-450 2c9 and 3A4  enzymes, 
fourteen  of  an oral dose is converted in to an active carboxylic acid metabolite that is 
responsible for  most of the angiotensin II receptor antagonist  activity.
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Dose: 25, 50 and 100mg
Contraindications 
• Hypersensitivity to the active substance or to any of the 
excipients  
• 2nd and 3rd Trimester of pregnancy 
• Lactation  
• Severe hepatic impairment
Adverse  effect
Nervous system disorders: 
Common: dizziness, vertigo 
Uncommon: somnolence, headache, sleep disorders
Cardiac disorder: 
Uncommon: palpitations, angina pectoris 
Vascular disorders: 
Uncommon: symptomatic hypotension (especially in patients
with intravascular volume depletion, e.g. patients with severe
heart failure or under treatment with high dose diuretics),
dose-related orthostatic effects, rash. 
Gastrointestinal disorders: 
Uncommon: abdominal pain, obstipation
General disorders and administration site conditions:
Uncommon: asthenia, fatigue, oedema 
Marketed Brands; LOSAR,COSAR
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HYDROXYPROPYLMETHYLCELLULOSE
Non-proprietary names:
BP: Hypromellose
JP: Hydroxypropylmethylcellulose
PhEur: Hypromellosum
USP: Hypromellose
2 Synonyms
Benecel MHPC; E464; hydroxypropyl methylcellulose;
HPMC; Methocel; methylcellulose propylene glycol ether;
methyl hydroxypropylcellulose; Metolose; Tylopur
3 Chemical Name and CAS Registry Number
    Cellulose hydroxypropyl methyl ether [9004-65-3]
4 Empirical Formula and Molecular Weight
hypromellose as a partly Omethylated and O-(2-hydroxypropylated) cellulose. It is 
available in several grades that vary in viscosity and extent of  substitution. Molecular 
weight is approximately 10 000 –1 500 000.
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6 Functional Category
Coating agent;  film-former; rate-controlling polymer for sustained release; stabilizing 
agent; suspending agent; tablet binder; viscosity-increasing agent.
7 Applications in Pharmaceutical Formulation
or Technology
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations.
In oral products, hypromellose is primarily used as a tablet binder,(1) in film-coating,
(2–7) and as a matrix for use in extended-release tablet formulations.(8–12) 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in tablets and capsules
Depending upon the viscosity grade, concentrations of 2–20% w/w are used for film-
forming solutions to film-coat tablets. Lower-viscosity grades are used in aqueous film-
coating solutions, while higher-viscosity grades are used with organic solvents. 
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Examples of film-coating materials that are commercially available include AnyCoat C, 
Spectracel, and Pharmacoat
Hypromellose is also used as a suspending and thickening agent in topical 
formulations. Hypromellose at concentrations between 0.45–1.0% w/w may be added 
as a thickening agent to vehicles for eye drops and artificial tear solutions.
 Hypromellose is also used as an emulsifier, suspending agent, and stabilizing agent in 
topical gels and ointments. As a protective colloid, it can prevent droplets and particles 
from coalescing or agglomerating, thus inhibiting the formation of sediments.
In addition, hypromellose is used in the manufacture of capsules, as an adhesive in 
plastic bandages, and as a wetting agent for hard contact lenses. It is also widely used 
in cosmetics and  food products.
8 Description
Hypromellose is an odorless and tasteless, white or creamywhite fibrous or granular 
powder.
Typical Properties
Acidity/alkalinity: pH = 5.5–8.0 for a 1% w/w aqueous
solution.
Ash: 1.5–3.0%, depending upon the grade and viscosity.
Autoignition temperature: 3608C
Density (bulk): 0.341 g/cm3
Density (tapped): 0.557 g/cm3
Density (true): 1.326 g/cm3
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Melting point: browns at 190–2000 C; chars at 225–2308C.
Glass transition temperature is 170–1808C.
Moisture content: hypromellose absorbs moisture from the atmosphere; the amount 
of water absorbed depends upon the initial moisture content and the temperature and 
relative humidity of the surrounding air
9 Safety
Hypromellose is generally regarded as a nontoxic and nonirritant material, although 
excessive oral consumption may have a laxative effect.
10 Incompatibilities
Hypromellose is incompatible with some oxidizing agents. Since it is nonionic, 
hypromellose will not complex with metallic salts or ionic organics to form insoluble 
precipitates.
POLYMETHACRYLATES(EUDRAGIT RSPO)
1 Nonproprietary Names
BP: Methacrylic acid–ethyl acrylate copolymer (1 : 1)
PhEur: Acidum methacrylicum et ethylis acrylas polymerisatum
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1 : 1
USPNF: Ammonio methacrylate copolymer
Methacrylic acid copolymer
Methacrylic acid copolymer dispersion
2 Synonyms
Acryl-EZE; Acryl-EZE MP; Eastacryl 30D; Eudragit; Kollicoat
MAE 30 D; Kollicoat MAE 30 DP; polymeric methacrylates.
3 Chemical Name and CAS Registry Number
Poly(butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl
methacrylate) [24938-16-7]
4 Empirical Formula and Molecular Weight
The PhEur 2005 describes methacrylic acid–ethyl acrylate copolymer (1 : 1) as a 
copolymer of methacrylic acid and ethyl acrylate having a mean relative molecular 
mass of about 250 000. The ratio of carboxylic groups to ester groups is about 1 : 1. It 
may contain suitable surfactants such as sodium dodecyl sulfate or polysorbate 80. An 
aqueous 30% w/v dispersion of this material is also defined in a separate monograph. 
Polyacrylate dispersion (30 per cent) is described in the PhEur 2005 as a dispersion in 
water of a copolymer of ethyl acrylate and methyl methacrylate having a mean relative 
molecular mass of about 800 000. It may contain a suitable emulsifier. Typically, the 
molecular weight of the polymer is5100 000.
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6 Functional Category
Film former; tablet binder; tablet diluents
7 Applications in Pharmaceutical Formulation
or Technology
Polymethacrylates are primarily used in oral capsule and tablet formulations as film-
coating agents.(1–17) Depending on the type of polymer used, films of different 
solubility characteristics can be produced. Polymethacrylates are also used as binders 
in both aqueous and organic wet-granulation processes. Larger quantities (5–20%) of 
dry polymer are used to control the release of an active substance from a tablet matrix. 
Solid polymers may be used in direct-compression processes in quantities of 10–
50%.Polymethacrylate polymers may additionally be used to form the matrix layers of 
transdermal delivery systems and have also been used to prepare novel gel 
formulations for rectal administration
8 Description
Polymethacrylates are synthetic cationic and anionic polymers of dimethylaminoethyl 
methacrylates, methacrylic acid, and methacrylic acid esters in varying ratios. Several 
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different types are commercially available and may be obtained as the dry powder, as 
an aqueous dispersion, or as an organic solution. A (60 : 40) mixture of acetone and 
propan-2-ol is most commonly used as the organic solvent.
12 Incompatibilities
Incompatibilities occur with certain polymethacrylate dispersions depending upon the 
ionic and physical properties of the polymer and solvent. For example, coagulation may 
be caused by soluble electrolytes, pH changes, some organic solvents, and extremes of 
temperature
14 Safety
Polymethacrylate copolymers are widely used as film-coating materials in oral 
pharmaceutical formulations. They are also used in topical formulations and are 
generally regarded as nontoxic and nonirritant materials. A daily intake of 2 mg/kg 
body-weight of Eudragit (equivalent to approximately 150mg for an average adult) may
be regarded as essentially safe in humans.
SODIUM STARCH GLYCOLATE
1 Nonproprietary Names
BP: Sodium starch glycollate
PhEur:Carboxymethylamylum natricum
USPNF: Sodium starch glycolate
2 Synonyms
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Carboxymethyl starch, sodium salt; Explosol; Explotab; Glycolys; Primojel; starch 
carboxymethyl ether, sodium salt; Tablo; Vivastar P.
3 Chemical Name and CAS Registry Number
Sodium carboxymethyl starch [9063-38-1]
4 Empirical Formula and Molecular Weight
The USPNF 23 states that sodium starch glycolate is the sodium salt of a carboxymethyl 
ether of starch, containing 2.8–4.2% sodium. The PhEur 2005 describes three types of 
material: Types A and B occur as the sodium salt of a cross-linked partly 
Ocarboxymethylated potato starch, containing 2.8–4.2% and 2.0–3.4% of sodium 
respectively. Type C is the sodium salt of a cross-linked by physical dehydration, partly 
O-carboxymethylated starch containing 2.8–5.0% sodium. Sodium starch glycolate may 
be characterized by the degree of substitution and crosslinking. The molecular weight 
is typically 5_105–1_106.
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6 Functional Category
Tablet and capsule disintegrant.
7 Applications in Pharmaceutical Formulation
or Technology
Sodium starch glycolate is widely used in oral pharmaceuticals as a disintegrant in 
capsule(1–6) and tablet formulations.(7–10) It is commonly used in tablets prepared by
either direct compression( 11–13) or wet-granulation processes.The   usual 
concentration employed in a formulation is between 2% and 8%, with the optimum 
concentration about 4%, although in many cases 2% is sufficient. Disintegration occurs 
by rapid uptake of water followed by rapid and enormous swelling.(17–20). Increasing 
the tablet compression pressure also appears to have no effect on disintegration time.
8 Description
Sodium starch glycolate is a white to off-white, odorless, tasteless, free-flowing powder. 
The PhEur 2005 states that it consists of oval or spherical granules, 30–100 mm in 
diameter, with some less-spherical granules ranging from 10–35 mm in diameter.
9 Incompatibilities
Sodium starch glycolate is incompatible with ascorbic acid.
10 Safety
Sodium starch glycolate is widely used in oral pharmaceutical formulations and is 
generally regarded as a nontoxic and nonirritant material. However, oral ingestion of 
large quantities may be harmful.
MAGNESIUM STEARATE
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BP: Magnesium stearate
JP: Magnesium stearate
PhEur: Magnesii stearas
USPNF: Magnesium stearate
2 Synonyms
Magnesium octa decanoate;  octa decanoic acid, magnesium salt; stearic acid, 
magnesium salt.
3 Chemical Name and CAS Registry Number
Octadecanoic acid magnesium salt [557-04-0]
4 Empirical Formula and Molecular Weight
C36H70MgO4 591.34
5 Structural Formula
[CH3(CH2)16COO]2Mg
6 Functional Category
Tablet and capsule lubricant
7 Applications in Pharmaceutical Formulation or Technology
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams
8 Description
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Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste.
The powder is greasy to the touch and readily adheres to the skin
9 Typical Properties
Crystalline forms: high-purity magnesium stearate has been isolated as a trihydrate, a 
dihydrate, and an anhydrate.
Density (bulk): 0.159 g/cm3
Density (tapped): 0.286 g/cm3
Density (true): 1.092 g/cm3
Flash point: 2508C
Flowability: poorly flowing, cohesive powder.
Melting range:
117–1508C (commercial samples);
126–1308C (high purity magnesium stearate).
Solubility: practically insoluble in ethanol, ethanol (95%), ether
and water; slightly soluble in warm benzene and warm
ethanol (95%).
Specific surface area: 1.6–14.8m2/g
9 Incompatibilities
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Incompatible with strong acids, alkalis, and iron salts. Avoid mixing with strong 
oxidizing materials. Magnesium stearate cannot be used in products containing aspirin, 
some vitamins, and most alkaloidal salts.
10 Safety
Magnesium stearate is widely used as a pharmaceutical excipient and is generally 
regarded as being nontoxic following
TALC
1 Nonproprietary Names
BP: Purified talc
JP: Talc
PhEur: Talcum
USP: Talc
2 Synonyms
Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium silicate; 
Luzenac Pharma; magnesium hydrogen metasilicate; Magsil Osmanthus; Magsil Star; 
powdered talc; purified French chalk; Purtalc; soapstone; steatite; Superiore. 3 
Chemical Name and CAS Registry Number Talc [14807-96-6]
4 Empirical Formula and Molecular Weight
Talc is a purified, hydrated, magnesium silicate, approximating to the formula 
Mg6(Si2O5)4(OH)4. It may contain small,
variable amounts of aluminum silicate and iron.
6 Functional Category
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Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule lubricant.
7 Applications in Pharmaceutical Formulation or Technology
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluent,although today it is less commonly used. However, it is widely used as a 
dissolution retardant in the development of controlled-release products.(4–6) Talc is 
also used as a lubricant in tablet formulations;( 7) in a novel powder coating for 
extended-release pellets;(8) and as an adsorbant.(9) In topical preparations, talc is 
used as a dusting powder, although it should not be used to dust surgical gloves; see 
Section 14. Talc is a natural material; it may therefore frequently contain 
microorganisms and should be sterilized when used as a dusting powder. Talc is 
additionally used to clarify liquids and is also used in cosmetics and food products, 
mainly for its lubricant properties
8 Description
Talc is a very fine, white to grayish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to the touch and free from grittiness
9 Incompatibilities
Incompatible with quaternary ammonium compounds
10 Safety
Talc is used mainly in tablet and capsule formulations. Talc is not absorbed systemically
following oral ingestion and is therefore regarded as an essentially nontoxic material. 
However However, intranasal or intravenous abuse of products containing talc can 
cause granulomas in body tissues, particularly the lungs.(16–18) Contamination of 
wounds or body cavities with talc may also cause granulomas; therefore, it should not 
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be used to dust surgical gloves. Inhalation of talc causes irritation and may cause severe
respiratory distress in infants
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METHODS
Estimation of  losartan potassium41:
In present study,  the spectrophotometric method was adopted for the estimation of
losartan potassium: using double beam U.V. spectrophotometer.
Preparation of Standard Stock Solution:
Stock solution: losartan potassium in methanol (100 mg in 100 ml).
Scanning: from the stock solution 4 µg/ml solution of losartan potassium
was prepared in0.1 N Hcl(1.2 pH buffer)  solution and scanned between 200-400nm.
The absorption maxima of 234 nm was selected and used for further studies.
b) Standard calibration curve of losartan potassium in 0.1 N Hcl solution: 
Preparation of standard stock solution:
Solution-A (1 mg/ml): 100 mg of Losartan potassium was accurately weighed
and transferred into a 100 ml volumetric flask. The drug was then dissolved and
diluted up to the mark with 0.1 N Hcl(1.2 pH buffer)
Solution-B (40 µg/ml): From solution-A, 4 ml was pipette and transferred into a
100 ml volumetric flask and diluted up to the mark with 0.1 N Hcl.  From this
solution-B, aliquots of 1.0, 2.0, 3.0, 4.0 and 5.0 ml  were transferred to 10 ml
volumetric flask and diluted up to the mark with  0.1N HCl buffer solution to
contain 4, 8, 12, 16 and 20 µg/ml of losartan potassium respectively.
The absorbance was measured in the UV-Visible spectrophotometer at
234nm using 0.1N  Hcl solution as blank and graph of  concentration  versus
absorbance  was  plotted.  .  Standard  plot  data  of  losartan  potassium  in  0.1N  Hcl
solution is reported 
Similarly the standard calibration curve of losartan potassium was prepared by using
phosphate buffer pH 6.8 and & 7.4 by using above said method.
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PREFORMULATION STUDIES.
Compatibility study
The compatability  study  was  carried out  for  the  losartan  potassium,  HPMC  K
100M,EUDRAGIT RSPO and SSG alone and combinations at ambient condition and
40°C / 75% RH for a period of one month and samples were subjected for FTIR
and DSC study for their characterization of  possible interaction b/w  drug and
career in solid state. 
Fourier-transformation infrared (FTIR) spectroscopy:
Excipients  are  integral  components  of  almost  all  pharmaceutical  dosage  forms.  To
investigate any possible interaction between the drug and the utilized polymers (HPMC
K  100  M,  EUDRAGIT  RSPO,AND  SSG),  IR  spectrum  of  pure  drug  (LOSARTAN
POTASSIUM) and its physical mixture was carried by using FTIR the range selected was
from 400cm-1 to 4000 cm-1
DSC study
Further  the  compatibility  between  drug  and  polymer  was  detected  by DSC  study.
Thermograms were obtained by using a differential scanning calorimeter (NETZSCH,
DSC 200PC, Japan) at a heating rate 10o C/min over a temperature range of 35-250o C.
The sample was hermetically sealed in an aluminium crucible. Nitrogen gas was purged
at the rate of 10 ml/min for maintaining inert atmospheres.
Trial batch for IR layer
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Sr.
No
Ingredients
(mg/tab)
T1 T1 T1 T2 T2 T2 T3 T3 T3
1 Losartan potassium 25 25 25 25 25 25 25 25 25
2 Ssg 10 15 20 - - - - - -
3 Cp - -- -- 10 15 20 - - -
4 Ccs - - - -- - - 10 15 20
5 lactose 50 50 50 50 50 50 50 50 50
6 Magnesium
stearate
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
7 Talc 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
8 %cdr 78.35 83.01 92.91 69.52 75.33 80.66 53.68 63.68 76.87
Trial batch for CR layer
Sr. No Ingredients (mg/tab)
F-1 F-2 F-3 F4
1 Losartan potassium 84 84 84 84
2 Hpmc k 100m 30 30 30 30
3 Eudragit rs-100 30 -- -- --
4 Ec n-50 -- 30 - --
5 Carbomer -- -- 30 --
6 Eudragit rspo -- -- -- 30
7 Magnesium stearate --- -- -- --
8 Talc 5 5 5 5
9 %cdr 72.73 78.53 83.19 90.98
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OPTIMIZATION
The runs or formulations, which are designed based on factorial design,
are evaluated for the response. The response values are subjected to multiple
regression analysis to find out the relationship between the factors used and the
response values obtained. The response values subjected for this analysis are; 
1. Friability 
2. Hardness
3. Percentage of Drug Release at 1st hour
4. Percentage of Drug Release at 8st hour. 
5. Percentage of Drug Release at 12st hour
The  duration  of  above  responses  were  chosen  for  the analysis  of  the
following relationship: 
1. To study the effect of amount of SSG (10-20)
2. To study the effect of amount of HPMC K 100 M.(30-50)
3.To study the effect of amount of EUDRAGIT RSPO(30-50)
3. To study the combined effect of SSG, HPMC K 100 M. and EUDRAGIT RSPO
The multiple regression analysis was done using design expert 8.0.4.1
software, which is specially meant for this optimization process. The results of
this analysis are presented in the table 5.4.1. 
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Using the regression coefficient of the factors, the polynomial equation for the response
is constructed. Only significantly, contributing factors are considered for the equation 
generation.
Composition of losartan potassium sustained release layer.
Ingredients F1 F2 F3 F4 F5 F6 F7 F8
LOSARTAN
POTASSIUM
84 84 84 84 84 84 84 84
HPMCK-100
(30 – 50mg)
30 30 50 50 30 50 50 30
EUDRAGIT RSPO
(30 – 50mg)
50 30 50 30 30 30 50 50
MAGNESIUM
STEARATE
5 5 5 5 5 5 5 5
TALC
5 5 5 5 5 5 5 5
Composition of losartan potassium immediate release layer.
Ingredients F1 F2 F3 F4 F5 F6 F7 F8
25 25 25 25 25 25 25 25
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LOSARTAN
POTASSIUM
SSG
(10-20)
10 10 10 20 20 10 20 20
MAGNESIUM
STEARATE
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
TALC
2.5 2.5 2.5 2.5 2.5 2.5 2.5 2.5
Procedure  for  IR  release  layer   granules  for  bilayer  tablets  of   losartan
potassium42: 
Direct compression granulation method43
 The drug,  polymers and other excipients used for  immediate (IR) layer was dried
properly and passed through sieve # 80 and accurately weighed sufficient quantity .of
components were  thoroughly mixed in a porceline mortar for a period of 15 mins. The
mixture were passed through # 20 and lubricated with magnesium stearate by further
blend  for  3  mins  and  finally  talc  was  added  to  the  blend  which  is  ready  for  the
compression.
Procedure for CR release layer  granules for bilayer tablets of  losartan potassium
Non aqueous Wet granulation 
The drug,  polymers and other excipients used for  controlled release(CR) layer was
dried  properly  and  passed  through  sieve  #  80  and  accurately  weighed  sufficient
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quantity .of  components were  premixed  in a porceline mortar for a period of 10 mins.
The powder mix was granulated by using  5% w/w isopropyl alcoholic solution . The
granules were allowed to dry in ambient condition fallowed by  subjected to tray drier
at   40°C until  properly dried.   The dried granules  were  passed through  #  20 and
lubricated with magnesium stearate by further blending for 3 mins and finally talc was
added to the blend which is ready for the compression. 
Compression of matrix tablets
LP  granules  of  either  immediate  or  sustained  release  granules  subjected  for
compression using 8mm round flat  punches  of  12 station lab scale semi automatic
rotary  tablet  punching  machine(CIP,  machinaries  pvt.  ltd.,  Ahmedabad).with
appropriate speead and pressure, composition of all the batches were represented in
table no
Compression of bilayer matrix tablets
The 75mg of equivalent weight of  pre weighed LP granules of sustained release layer
were  first  subjected  in  the  die  cavity  and  slightly  compressed  to  adjust  uniform
spreading of  the  25 mg of equivalent weight  of  pre weighed LP granules of Immediate
release  layer  was   subsequently  placed  in  the  die  cavity  and  compressed  with  an
constant pressure and speed. 
postcompression parameters for immediate layers of losartan potassium
Postcompression parameters for sustained release layers of losartan potassium
Precompression parameters for Bilayer tablets containing immediate and 
sustained release  layers of losartan potassium44. 
a) Angle of Repose
b) Bulk density and tapped density
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c) Hausner ratio.  
d) Carr’s index
(a) Bulk density 
Apparent bulk density ρb was determined by pouring the blend into a graduated
cylinder. Thebulk volume (Vb) and weight of powder (M) was determined.
The bulk density was calculated using the formula.
                   ρb =      M
                                 Vb
(b) Tapped density 
The measuring cylinder containing a known mass of blend was tapped
for a fixed  time. The minimum volume (Vt) occupied in the cylinder and the
weight (M) of the blend was  measured.  The tapped density  (ρt)  was calculated
using the formula.
          M
          Vt
(c) Compressibility index 
The simplest way for measurement of flow of powder is its compressibility, a 
indication of the ease with which a material can be induced to flow is given by 
compressibility index (I) which is calculated as follows                
                                           ρ t - ρb
                                 I  =                     ×100         
                                   ρt           
Where, ρt = Tapped density,   ρb = Bulk density
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ρ t 
=
Compressibility index as an indication of powder flow properties
Carr's Index (%) Type of Flow
>12 Excellent
12.0-16 Good
18-21 Fair to passable
23-35 Poor
33-38 Very poor
>40 Extremely poor
Hausner ratio
Hausner ratio (HR) is an indirect index of ease of powder flow. It is 
calculated by the following formula
Pt
Ρb 
Where, ρt is tapped density and ρb is bulk density.Lower Hausner ratio (<1.25) 
indicates better flow properties than higher ones (> 1.25).
(e) Angle of repose 
Angle of Repose was determined using funnel method. The blend was poured through a
funnel that can be raised vertically until a specified cone height (h) was obtained. 
Radius of the heap (r) was measured and angle of repose (θ) was calculated using the 
formula
                                                                            tan ө = h/r
                                            Therefore; θ = tan -1  
Where, θ is Angle of Repose; h is height of cone; r is radius of cone
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HR =
Evaluation of Postcompression parameters  for  immediate and sustained bilayer 
tablet of  losartan potassium45. 
a) Hardness
b) Thickness
c) Weight variation,
d) Friability
e) Drug content uniformity 
f) In vitro drug release studies.
G) swelling study
h)   stability study
Tablet Thickness and size45
     Thickness and diameter of tablets were important for uniformity of tablet size. 
Thickness and diameter was measured using venire caliper.
Tablet Hardness
          The resistance of tablets to shipping or breakage under conditions of storage, 
transportation and handling before usage depends on its hardness. The hardness of 
tablet of each formulation was measured by Monsanto hardness tester. The hardness 
was measured in kg/cm2.
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Angle of Repose(o) Type of Flow
<25 Excellent
25-30 Good
30-40 Passable
>40 Very poor
 Friability
   Friability is the measure of tablet strength. Electrolab EF-2 friabilator (USP) was used
for testing the friability using the following procedure. Twenty tablets were weighed
accurately and placed in the tumbling apparatus that revolves at 25 rpm dropping the
tablets through a distance of six inches with each revolution. After 4 min, the tablets
were weighed and the percentage loss in tablet weight was determined. 
 % loss = [(Initial wt. of tablets – Final wt. of tablets)/ Initial wt. of tablets] ×100
 Uniformity of weight
         Twenty tablets were selected at random and the average weight was calculated.
Weight Variation was calculated and  was compared with I. P. standards.
Determination of drug content46
Three tablets were powdered and powder equivalent to weight of one tablet (100mg)
was  transferred  to  100ml  volumetric  flask  containing  distilled  water.  For  ensuring
complete solubility sonication was done for 30 mins.Solution was suitably diluted and
the absorbance was determined by UV-Visible spectrophotometer at 250nm.
Disintegration test (DT) 47
In vitro drug release studies16
The prepared matrix tablets were subjected to in-vitro dissolution studies using an 8
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station USP dissolution apparatus (Electrolab, TDT-08L, Dissolution tester USP). The
dissolution studies were carried out in pH 1.2 for 3 hrs, in pH 6.8 for  4 hr & pH 7.4
for  4 hrs at 37 ± 0.50  c and 50 rpm . At regular time interval, 5 ml of sample was
withdrawn  from  the  dissolution  medium  and  replaced  with  equal  volume  of
methanol.  After filtration and appropriate dilution, the samples were analyzed at
234 nm for losartan potassium against blank using UV-Visible spectrophotometer.
The amount of drug present in the samples was calculated using standard curve.
 Data analysis48: 
The  dissolution  profile of  most  satisfactory  formulation  was  fitted to zero order,
first order and Higuchi  model  to  ascertain  the kinetic modeling of the drug release.
The  methods  were  adopted for deciding  the  most  appropriate  model.
Cumulative percent drug released versus time (Zero order kinetic model)
 Log cumulative percent drug remaining versus time (First order kinetic model)
 Cumulative percent drug released versus square root of time (Higuchi’s model).
Log percentage drug released Vs log time (Peppas plots)
• Zero order release rate kinetics:
To study the Zero–order release kinetics the release rate data are fitted to the
following equation.      
F = K.t
Where ‘F’ is the fraction of drug release, ‘K’ is the release rate constant and‘t’ is
the release time.
When  the  data  is  plotted  as  cumulative  percent  drug  release  versus
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time, if the plot is linear then the data obeys Zero-order release kinetics,
with a slope equal to K0.
• Higuchi release model:
To study the Higuchi release kinetics, the release rate data were fitted to the
following equation,
F = K .t1/2
Where,   ‘F’ is the amount of drug release,
    ‘K’ is the release rate constant, and 
               ‘t’ is the release time.
When the data is plotted as a cumulative drug released versus square
root  of  time,  yields  a  straight  line,  indicating  that  the  drug was  released by
diffusion mechanism. The slope is equal to ‘K’.
• Korsmeyer and Peppas release model:
The release rate data were fitted to the following equation,
Mt /M∞ = K. t
n
Where, Mt /M∞ is the fraction of drug release,  ‘K’ is the release constant,‘t’ is the release 
time, and  ‘n’ is the diffusion exponent for the drug release that is dependent on the 
shape of the matrix dosage form
The value of release exponent (n) was found to be a function of polymer used and the 
physicochemical property of a drug molecule itself. 
Kinetic results revealed that, all the formulations followed zero order kinetics as 
correlation coefficient (r2) values (0.9738-0.9921) are higher than that of first order 
release kinetics.
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 The prepared hydrophilic bilayer matrix tablets showed Non-Fickian (anomalous) 
release, as the values of release exponent (n) lies between 0.5594-0.8662 with their 
correlation coefficient (r2) values between 0.9778-0.9985, indicating that coupled 
diffusion, polymer swelling and relaxation were involved in the release process
 swelling study
azar
 The extent of swelling was measured in terms of % weight gain by the tablet.  One
tablet from each formulation was weighed and kept in Petri dish containing 20 ml of
phosphate  buffer  of  pH  6.8.  At  the  end  of  specified  time  intervals  tablets  were
withdrawn from Petri dish and excess buffer blotted with tissue paper and weighed.  
The % weight gain by the tablet was calculated by formula:
    Mt–M0
                               %Swelling index =                  ×100
  Mt
Where, Mt – weight of tablets at time‘t’; M0 – weight of tablets time‘0’
Stability Studies: 
STABILITY OF A DRUG CAN BE DEFINED AS THE TIME FROM THE DATE
OF MANUFACTURE AND THE PACKAGING OF THE FORMULATION,  UNTIL ITS
CHEMICAL OR BIOLOGICAL ACTIVITY IS NOT LESS THAN A PREDETERMINED
LEVEL OF LABELED POTENCY AND ITS PHYSICAL CHARACTERISTICS HAVE NOT
CHANGED APPRECIABLY OR DELETERIOUSLY.
The purpose of stability testing is to provide evidence on how the quality of a
drug substance or drug product varies with time under the influence of a variety of
environmental factors such as temperature, humidity and light and to establish a re-test
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period for the drug substance or a shelf life for the drug product and recommended
storage conditions. 
  The  International  Conference  on  Harmonization  (ICH)  guidelines  titled
“Stability Testing of New Drug substance and Products” (QIAR2) describes the stability
test requirements for drug registration applications in the European Union, Japan and
the United States of America.
ICH specifies the length of study and storage conditions.
Long-term Testing:            250C  20C/60 % RH ± 5% for 3 Months.
Accelerated Testing:            400C ± 20C/75 % RH ± 5% for 3 Months.
Method 
The selected formulations were packed in amber- colored bottles, which were tightly 
plugged with cotton and capped with aluminum. They were then stored at 25 ºC / 60% 
RH, and 40 ºC / 75% RH for 90 days and evaluated for their hardness, friability, drug 
content, disintegration time and in vitro dissolution study.
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RESULTS    
5. RESULTS
5.1 Preformulation Studies:
5.1.1 Organoleptic Properties:
a) Colour:  A small quantity of Losartan potassium powder was taken in butter paper
and viewed in well-illuminated place.
b) Taste and odour: Very less quantity of Losartan potassium was used to get taste with
the help of tongue as well as smelled to get the odour.
Table no: 12 Organoleptic Properties for Losartan potassium
Test Specification/limits Observations
Colour White White
Taste Bitter Bitter
Odour  Odourless Odourless
STD Calibration curve of  losartan potassium in 1.2 ph solution
                    
 
*Average of three determinations
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Concentration (µgm/ml) Absorbance (mean ± Sd)
0 0.00 ±0.00         
4 0.144 ±0.005          
8 0.262±0.004
12 0.403±0.003
16 0.506±0.004
20 0.62± 0.005
RESULTS    
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Calibration curve of  losartan potassium in 6.8 ph solution
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Concentration (µgm/ml) Absorbance (mean ± Sd)
0 0.00
4 0.123
8 0.241
12 0.386
16 0.487
20 0.593
RESULTS    
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Calibration  curve of  losartan potassium in 7.4 ph solution.
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Concentration (µgm/ml) Absorbance (mean ± Sd)
0 0.00
4 0.157
8 0.276
12 0.418
16 0.515
20 0.634
RESULTS    
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Compatibility  studies of losartan potassium with the exiepient.
Pure losartan potassium
Functional group
Range
Observed range in pure
drug
C=N stretching 1515-1590 1575
OH 1160 -1270 1259
1,4 di substituted
phenyl ring
800-850 842
1,6 substituted
phenyl ring
720-780 763
C-Cl 550-850 560
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RESULTS    
Post compression study of IR layer
SL.
No
TESTS Specification T-1a T-1b T-1c
1. Thickness
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RESULTS    
(mm)* 3.42 – 3.98 mm 3.42±0.05 3.44±0.01 3.46±0.005
2.
Hardness*
(kg/cm2) 5.0 - 6.0 kg/cm2
5.3±0.25 5.3±0.20 5.1±0.35
3.
Friability*
(%)*
Not more than
1% 0.25±0.04 0.30±0.02 0.25±0.04
4.
Average
weight*
(mg)
90- 100 mg 90 95 100
5.
Weight
variation*
± 7.5% from
the average
weight 2.0% 1.2% 2.1%
SL.
No
TESTS Specification T-2a T-2b T-2c
1.
Thickness
(mm)* 3.42 – 3.98 mm 3.45±0.05 3.41±0.01 3.46±0.005
2.
Hardness*
(kg/cm2) 5.0 - 6.0 kg/cm2
5.4±0.22 5.4±0.19 5.2±0.25
3.
Friability*
(%)*
Not more than
1% 0.25±0.04 0.30±0.02 0.25±0.04
4.
Average
weight*
(mg)
90- 100 mg 90 95 100
5.
Weight
variation*
± 7.5% from
the average
weight 2.0% 1.2% 2.1%
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RESULTS    
SL.
No
TESTS Specification T-3a T-3b T-3c
1.
Thickness
(mm)* 3.42 – 3.98 mm 3.45±0.05 3.44±0.01 3.47±0.005
2.
Hardness*
(kg/cm2) 5.0 - 6.0 kg/cm2
5.3±0.25 5.3±0.20 5.1±0.35
3.
Friability*
(%)*
Not more than
1% 0.25±0.04 0.30±0.02 0.25±0.04
4.
Average
weight*
(mg)
90- 100 mg 90 95 100
5.
Weight
variation*
± 7.5% from
the average
weight 2.0% 1.2% 2.1%
Post compression study of CR layer
SL.
No
TESTS SPECIFICATION F-1 F-2 F-3 F-4
1. Thickness
(mm)*
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RESULTS    
3.42 – 3.78 mm 3.59±0.05 3.64±0.01 3.56±0.005 3.58±0.01
2.
Hardness*
(kg/cm2) 5.0 - 7.0 kg/cm2
6.3±0.25 6.5±0.20 6.1±0.35 6.3±0.26
3.
Friability*
(%)*
Not more than 1%
0.35±0.04 0.30±0.02 0.45±0.04 0.41±0.01
4.
Average
weight*
(mg)
150 mg 150 150 150 150
5.
Weight
variation*
± 7.5% from the
average weight 2.0% 1.2% 2.1% 1.2%
Precompression parameters for Losartan potassium fast dissolving 
layer. 
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RESULTS    
Batch
code
Bulkdensity
(gm/cm3)
Tappeddensity
(gm/cm3)
Carr’sindex
(IC)
Hausnerratio
        (HR)
Angel of
repose(θ)
F1 0.51 0.59 13.5 1.15 30.21
F2 0.48 0.55 12.7 1.14 31.23
F3 0.46 0.52 11.5 1.13 29.56
F4 0.47 0.53 11.3 1.12 27.58
F5 0.48 0.56 14.2 1.16 28.42
F6 0.5 0.58 13.79 1.16 29.78
F7 0.46 0.55 16.36 1.19 30.11
F8 0.45 0.53 15.09 1.17 30.29
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RESULTS    
Precompression parameters for losartan potassium sustained release layer.
Batch
code
Bulkdensity
(gm/cm3)
Tappeddensity
(gm/cm3)
Carr’sindex
(IC)
Hausnerratio
        (HR)
Angel of
repose(θ)
F1 0.467 ± 0.29 0.5914 ± 0.19 21.9 ±0.13 1.26±0.16 30.6 ±0.28
F2 0.478 ±0.32 0.598 ± 0.27 20 ± 0.17 1.25±0.17 29.1 ±0.25
F3 0.447 ± 0.39 0.573 ± 0.32 21.9 ±0.23 1.28±0.14 29.7 ±0.23
F4 0.469 ± 0.25 0.59 ± 0.19 20.5 ±0.31 1.25±0.14 29.3 ±0.23
F5 0.469 ± 0.27 0.577 ± 0.39 18.5 ±0.33 1.23±0.12 27.7 ±0.35
F6 0.449 ± 0.31 0.555 ± 0.15 18.9 ±0.41 1.23±0.16 27.3 ±0.25
F7 0.465 ± 0.42 0.552 ± 0.27 15.7 ±0.28 1.18±0.13 26.4 ±0.55
F8 0.472 ± 0.4 0.589 ± 0.3 19.8 ±0.09 1.24±0.19 29.6 ±0.43
Evaluation parameters of bilayer layer matrix tablet.
SL.
No
TESTS SPECIFICATION F-1 F-2 F-3 F-4
1.
Thickness
(mm)* 3.42 – 3.78 mm 3.59±0.05 3.64±0.01 3.56±0.005 3.58±0.01
2. Hardness* 6.3±0.25 6.5±0.20 6.1±0.35 6.3±0.26
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RESULTS    
(kg/cm2) 5.0 - 7.0 kg/cm2
3.
Friability*
(%)*
Not more than 1%
0.25±0.04 0.30±0.02 0.25±0.04 0.21±0.01
4.
Average
weight*
(mg)
203- 253 mg 223 203 243 233
5.
Weight
variation*
± 7.5% from the
average weight 2.0% 1.2% 2.1% 1.2%
SL.
No
TESTS SPECIFICATION F-5 F-6 F-7 F-8
1.
Thickness
(mm)* 3.42 – 3.78 mm 3.46±0.02 3.59±0.04 3.64±0.02 3.56±0.01
2.
Hardness*
(kg/cm2) 5.0 - 7.0 kg/cm2
6.5±0.25 6.3±0.43 6.5±0.503 6.1±0.15
3.
Friability*
(%)*
Not more than 1%
0.25±0.03 0.40±0.04 0.41±0.05 0.35±0.03
4.
Average
weight*
(mg)
203- 253 mg 213 223 253 233
5.
Weight
variation*
± 7.5% from the
average weight 2.1% 2.0% 1.2% 2.1%
Where, * All values are mean ± SD, n =3
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f1 f2 f3 f4 f5 f6 f7 f8
3.35
3.4
3.45
3.5
3.55
3.6
3.65
3.7
THICKNESS
THICKNESS
F1 F2 F3 F4 F5 F6 F7 F8
5.8
5.9
6
6.1
6.2
6.3
6.4
6.5
6.6
HARDNESS
HARDNESS
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RESULTS    
F1 F2 F3 F4 F5 F6 F7 F8
0
0.05
0.1
0.15
0.2
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0.4
0.45
FRIABILITY
FRIABILITY
5.6.3  Drug Content:
Table no.  18.  Drug Content Uniformity of tablet formulations ( F1-F8)
Formulations Code      % Drug Content*
F-1 99.66±0.62
F-2 97.5±0.76
F-3 99.16±0.47
F-4 99.66±0.60
F-5 99.66±0.33
F-6 99.9±0.33
F-7 98.16±0.34
F-8 99.16±0.47
    Where,
         * All values are mean ± SD, n =3.
TIME(hr)
%CDR
F1 F2 F3 F4
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RESULTS    
1.2 ph
0 0 0 0 0
1 9.005 13.17 9.54 9.54
2 12.98 16.60 13.62 15.10
3 14.63 19.38 18.94 20.02
4 33.83 35.91 26.83 26.02   
  6.8 ph
5 41.19 41.91 27.28 29.85
6 45.96 46.47 28.80 33.53
7 51.67 52.67 32.89 40.46
8 61.33 63.69 40.73 46.62  
  7.4 ph
9 67.32 67.11 46.55 56.19
10 78.75 73.64 55.99 61.25
11 83.25 79.53 63.88 70.10
12 88.44 89.75 67.54 74.96
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TIME(hr)
  1.2 ph
F5 F6 F7 F8
0 0 0 0 0
1 18.14 13.17 17.60 9.54
2 19.05 15.26 18.78 13.22
3 22.92 17.49 20.63 16.65
4 29.03 29.71 30.48 26.41  
 6.8 ph
5 32.42 35.26 32.15 31.43
6 37.04 41.12 33.96 35.14
7 45.31 44.46 35.78 37.12
8 53.58 55.71 44.68 48.83  
 7.4 ph
9 72.57 63.16 56.16 62.88
10 86.16 71.06 61.92 76.32
11 88.40 77.52 66.90 79.22
12 94.82 82.67 74.32 81.47
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             Regression analysis and correlation coefficient
Zero order First order Higuchi Korsmeyer peppas
r2 N r2 N r2 n r2 N
F1 0.982 7.668 0.942 0.066 0.882 28.08 0.914 1.641
F2 0.979 7.387 0.981 7.208 0.975 34.10 0.943 1.578
F3 0.969 5.219 0.975 5.288 0.892 19.54 0.965 0.790
F4 0.989 5.982 0.955 0.075 0.907 22.28 0.983 0.840
F5 0.982 7.668 0.942 0.066 0.882 28.08 0.914 1.641
F6 0.995 6.768 0.945 0.054 0.904 24.77 0.993 1.056
F7 0.968 4.935 0.934 0.035 0.907 18.93 0.958 0.734
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F8 0.976 7.807 0.887 0.075 0.872 27.98 0.973 1.001
Swelling study of bilayer matrix tablets of losartan potassium
Tim
e
(hrs
)
                                    % Swelling study
F1 F2 F3 F4 F5 F6 F7 F8
  0 0 0 0 0 0 0 0 0
1 33.4
3
35.5
5
36.8
8
26.0
3
27.7
9
35.2
9
37.1
5
34.5
4
2 42.0
7
43.4
5
47.7
4
41.0
1
40 46.3
1
46.2
3
43.5
6
3 47.5
2
49.8
7
52.8
1
49.8
9
48.0
4
53.9
7
49.2
3
49.2
3
4 52.5
5
56.6
2
58.8
1
55.1
9
55.4
3
59.6
3
53.1
5
53.9
1
5 57.1
1
60.1
9
62.9
0
60.8
4
59.4
2
64 56.8
5
56.4
5
6 60.7
3
65 65.5
3
64.0
9
64.3
7
67.1
1
61.1
9
60.1
9
7 63.3
8
67.9
8
69.0
4
67.4
1
69.5
2
70.2
7
65.4
3
64.3
9
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8 64.8
8
65.9
9
72.3
8
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10 61.2
1
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2
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1
11 57.6
8
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7
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9
81.5
4
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1
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1
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6
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Table 5.4.1 Design and Summary Response Data
Run SSG
HPMC
k-100 
m
EUDRAGIT
RSPO
Hardnes
s
(Kg/cm2 
)
Friabilit
y
(%)
      n
VALUE
1 10 30 30 6.3 0.25   1.641
2 20 50 30 6.5 0.30 1.578
3 10 30 50 6.1      0.25 0.79
4 20 30 50 6.3 0.21 0.84
5 20 30 30 6.5 0.25 1.0
6 10 50 50 6.3 0.40 1.0
7 20 50 50 6.5 0.41 0.734
8 10 50 30 6.1 0.35 1.0
               
                SSG: Sodium Starch Glycolate
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Run SSG
HPMC
k-100
m
EUDRAGIT 
RSPO
%CDR
at 1 (hr)
%CDR at
8 (hr)
%CDR
at 12 (hr)
1 10 30 30 9.72 61.33   88.44
2 20 50 30 13.17 63.69 89.75
3 10 30 50 9.54      40.73 67.54
4 20 30 50 9.54 46.62 74.96
5 20 30 30 18.14 53.58    94.82
6 10 50 50 13.17 55.71 82.67
7 20 50 50 17.60 44.69 74.32
8 10 50 30 9.54 48.83 81.47
Response: R1 (hardness)
 
 5.4.1.1(a) ANOVA for factorial model
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Table 5.4.1.1(b) Estimated Regression Coefficients
Factor 
Coefficient
Estimate 
DF 
Intercept 4.0 1 
                         A- SSG  -0.25 1 
Final Equation in Terms of Coded Factors: 
R1 =  Hardness  =+4.00-0.25 * A
Figure 5.4.1.1(a): Correlation between actual and predicted values for Friability
(R1)
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Source 
Sum of
Squares
DF 
Mean
Square
F Value Prob >F 
Model 0.50 1 0.50 6.0 0.0498
A-SSG 0.50 1 0.50 6.0 0.0498
Residual 0.50 6 0.083 - -
Cor Total 1.0 7 - - - 
RESULTS    
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 Figure 5.4.1.1(b): 3-D graph showing effect of SSG, HPMC K 100M on 
(R1) Hardness
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  A: SSG  
  B: HPMC K 100M  
Response: R2 (Drug release after 1hr)
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Table 5.4.1.2(a) : ANOVA for factorial model
Source 
Sum of
Squares
DF 
Mean
Square
F Value Prob >F 
Model 25.45 3 8.48 0.57 0.6635
    SSG 3.99 1 3.99 0.27 0.6317
Hpmc k 100m 1.52 1 1.52 0.10 0.7650
Eudragit RSPO 19.94 1 19.94 1.34 0.3112
Residual 59.46 4 14.87 - -
Cor Total 84.91 7 - - - 
Table 5.4.1.2(b): Estimated Regression Coefficients
Factor 
Coefficient
Estimate 
DF 
Intercept  7.49 1 
                          A-SSG  0.71 1 
   B- HPMC K 100M   -0.44 1 
C-Eudragit RSPO  1.58 1 
Final Equation in Terms of Coded Factors: 
R2 =Drug release after 1hr = +7.49+0.71  * A-0.44 * B+1.58   * C 
Figure 5.4.1.2(a): Correlation between actual and predicted values for Hardness
(R2)
98
RESULTS    
Design-Expert® Software
R2Drug release after 1hr
Color points by value of
R2Drug release after 1hr:
10.88
2.15
Actual
P
re
d
ic
te
d
Predicted vs. Actual
2.00
4.00
6.00
8.00
10.00
12.00
2.00 4.00 6.00 8.00 10.00 12.00
Figure 5.4.1.2(b): 3-D graph showing effect of SSG,HPMC K 100M on Drug release
after 1hr (R2)
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  A: SSG    B: HPMC K 100M  
Response: R3 (Drug release 8hr)
Table 5.4.1.3(a): ANOVA for factorial model
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Source 
Sum of
Squares
DF 
Mean
Square
F Value Prob >F 
Model 196.52 1 196.52 6.95 0.0387
C-Eudragit RSPO 196.52 1 196.52 6.95 0.0387
Residual 169.55 6 28.26 - -
Cor Total 366.06 7 - - - 
Table 5.4.1.3(b): Estimated Regression Coefficients
Factor 
Coefficient
Estimate 
DF 
Intercept 49.37 1 
                          C-Eudragit RSPO  -4.96 1 
Final Equation in Terms of Coded Factors: 
R3 = R3 Drug release 8hr  = +49.37- 4.96  * C 
Figure  5.4.1.3(a):  Correlation  between  actual  and  predicted  values  for  Drug
release 8hr (R3)
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Figure 5.4.1.3(b): 3-D graph showing effect of SSG, Hpmc K100 M on Drug release
8hr (R3)
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  A: SSG    B: HPMC K 100M  
Response: R4 (Drug release 12 hr)
Table 5.4.1.4(a):  ANOVA for factorial model
Source 
Sum of
Squares
DF 
Mean
Square
F Value 
Prob
>F 
Model 385.39 2 192.70 7.27 0.0331
A-SSG 0.64 1 0.64 0.024 0.8828
C-Eudragit RSPO 384.75 1 384.75 14.51 0.0125
Residual 132.58 5 26.52 - - 
Cor Total 517.98 7 - - - 
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Table 5.4.1.4(b): Estimated Regression Coefficients
Factor 
Coefficient
Estimate 
DF 
Intercept 79.15 1 
                          A-SSG  -0.28 1 
   C- Eudragit RSPO  -6.94 1 
Final Equation in Terms of Coded Factors: 
R4 = R4 Drug release 12hr  = +79.15 -0.28   * A -6.94  * C
 
Figure  5.4.1.4(a):  Correlation  between  actual  and  predicted  values  for  Drug
release 12hr  (R4)
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Figure 5.4.1.4(b): 3-D graph showing effect of SSG, HPMC K100 M on Drug release
12hr  (R4)
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  A: SSG    B: HPMC K 100M  
Response: R5 (Friability)
Table 5.4.1.4(a):  ANOVA for factorial model
Source 
Sum of
Squares
DF 
Mean
Square
F Value 
Prob
>F 
Model 0.015 6 2.529 22.48 0.1601
A-SSG 2.813 1 2.813 25 0.1257
B-HPMC K 100M 5.513 1 5.513 49 0.0903
C-Eudragit RSPO 3.125 1 3.125 2.78 0.3440
RESIDUAL 1.125 1 1.125 - - 
Cor Total 0.015 7 - - -
Table 5.4.1.4(b): Estimated Regression Coefficients
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Factor 
Coefficient
Estimate 
DF 
Intercept 0.57 1 
                          A-SSG  0.019 1 
   B-HPMC K 100M  0.026 1 
C- Eudragit RSPO -6.250 1
Final Equation in Terms of Coded Factors: 
R5 = Friability  =
+0.97500
-0.028250               * SSG
-4.50000E-003   * HPMC K 100M
-8.50000E-003   * Eudragit RSPO
+3.75000E-004   * SSG * HPMC K 100M
+4.25000E-004   * SSG * Eudragit RSPO
+3.75000E-005   * HPMC K 100M * Eudragit RSPO
Correlation between actual and predicted values for Friability(R5)
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3-D graph showing effect of SSG, HPMC K100 M on Friability (R5)
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Response: R6 (n value)
(a):  ANOVA for factorial model
Source 
Sum of
Squares
DF 
Mean
Square
F Value 
Prob
>F 
Model 0.43 2 0.21 2.61 0.1678
A-SSG 0.012 1 0.012 0.15 0.7162
C-Eudragit RSPO 0.42 1 0.42 5.06 0.0743
RESIDUAL 0.41 5 0.082 - - 
Cor Total 0.84 7 - - -
(b): Estimated Regression Coefficients
Factor 
Coefficient
Estimate 
DF 
Intercept 1.08 1 
                          A-SSG  -0.039 1 
C- Eudragit RSPO -0.23 1
Final Equation in Terms of Coded Factors:
 R6 n value  = +1.08 -0.039 * A-0.23 * C
Correlation between actual and predicted values for n-value(R6)
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3-D graph showing effect of SSG, HPMC K100 M on n-value (R6)
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TABLE 5.4.1.5 Composition of the optimized formula.
*INGREDIENTS R 
LOSARTAN POTASSIUM 100
Sodium Starch Glycolate 20
HPMC K100M 30
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EUDRAGIT RSPO  35.87
Magnesium Stearate  5
Talc 5
TOTAL  195.87
*All the quantities expressed are in mg / tablet.
TABLE 5.4.1.6 Comparison between the experimental (E) and predicted (P) values
for the most probable optimal formulation
Optimized
Formulation
Dependable Variables
Friability
(%)
Hardness
(kg/cm2 )
Drug
release at
1 hr
Drug
release at
8 hr
Drug
release
at 12 hr
n-value
Predicted 0.37 5.4 7.97 51.41 81.73 1.132
Experiment 0.33 5.0 10.30 60.35 89.10 0.924
Optimal formula
TIME 1 2 3 4 5 6 7 8 9 10 11 12
%CDR 10.3
0
19.0
5
24.9
2
29.0
3
34.4
2
39.04 49.3
1
60.3
5
72.5
7
78.1
6
83.4
0
89.1
0
Sr. No. Parameters Results
1. Appearance Good 
2. Hardness 5.0kg/cm2
3. Friability 0.33%
4. Drug content 99.52 %
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7. % Swelling index at 12 h 83.83%
8. In- vitro drug release 89.10
5.4.2 Stability studies
Table 5.4.2: At ambient condition (25±2°C and relative humidity 60± 5%)  
Time Hardness
(Kg/cm2)
Friability
(%)
Drug content
(%)
Cumulative %
drug released
at 12 hr
Initial 6.3±0.25 0.25 98.69±0.69 89.10
First
Month
6.3±0.23 0.25 98.53±0.84
89.10
Second
Month
6.3±0.32 0.27 98.58±0.57
89.10
Third
Month
6.3±0.30 0.29 98.63±0.57
89.10
At elevated temperature (40±2°C and relative humidity 75± 5%)
Time Hardness
(Kg/cm2)
Friability
(%)
Drug
content
(%)
Cumulative %
drug released at
12 hr
Initial 6.3±0.25 0.25 98.69±0.69 89.10
First
Month
6.3±0.23 0.25 98.53±0.84
89.10
Second
Month
6.3±0.32 0.27 98.58±0.57
89.10
Third
Month
6.3±0.30 0.29 98.63±0.57
89.08
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6. DISCUSSION
Bilayer tablets are novel drug delivery system were combination of single
or two drugs used as a single unit having bimodal release profile to improve
patient compliance, for the better management of multiple complications. In the
present study bilayer tablet immediate and sustained release of losartan potassium
were prepared with an objective of  improving patient compliance by effective
management of hypertension.
The bilayer tablets were prepared by compressing losartan potassium as
fast dissolving layer and sustained   releasing layer. 
Identification:
The losartan potassium was estimated using buffer solution(1.2,6.8 and 7.4
pH) and the calibration curve was constructed in this solution at 234 nm as shown in
Table-5 and fig-6. The method obeys Beer-Lambert‘s law in the studied range of 4-20
mcg/ml with high  ‗r‘ value of  >0.996 and low SD value suggested that method was
reproducible and hence suitable for estimation of losartan potassium.
Losartan  potassium was formulated as fast dissolving layer using
sodium starch  glycolate  as superdisintegrants in different concentration. And it
prepared as sustained release layer using matrix forming material like HPMC,
and eudragit rspo  in different combination. 
FTIR Study:
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IR  (KBr)  cm-1 of  pure  drug  losartan  potassium  exhibited  characteristics
absorption bands in the IR region as mentioned below:
The peak at 3227.0 due to hydrogen bonding caused by –NH  & -OH groups. The
peak at 3077 due to aromatic -CH stretching. The group of peaks between 2956 to 2671
may be due to –CH-H stretching of –CH3 and –CH2 groups.1575 may be due to  –C=N
stretching.  1575,  1472 may be due to C=C ring stretching 1423 may be due to -CN
stretching, 1422 & 1340 may be due to –CH bending, 1260 & 1188 may be due to –OH &
-CO bending, 844 may be due to  1, 4 – di-substituted  phenyl ring, 754 may be due to
substituted phenyl ring, 565 may be due to –C-Cl.
The IR data of the formulation was compared with the standard spectrum of pure drug
losartan  potassium  and  the  characteristic  peaks  associated  with  specific  functional
groups and bonds of the molecule and their presence/absence in the polymeric carrier
(formulation) were noted. The IR spectrum of the formulation showed that there is no
significant evidence for interaction between drug and the polymer. Peaks of both drug as
well as formulation were observed and interpreted. So this clearly suggest that the drug
has not undergone any interaction with the polymer in the formulation, as there is no
any  shift  in  the  positions  of  the  characteristic  absorption  bands  of  drug  in  the
formulation.
DSC study:
Micromeritic  properties:
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In the present study, direct compression method was adopted for IR layer. Hence the
mixture  of  drug and ssg  should  posses  good flow and compaction properties.  Plain
losartan potassium exhibited angle of repose value of 41.22 ± 0.16o indicating poor flow
property.  It was furthersupported by high  Carr’s index (31.19  ± 0.14) and Hausner’s
ratio (1.45 ± 0.07). Hence lubricants were added to improve the flow property of drug.
The angle of repose of all the blend was within range of 27.58 to 31.21o indicated
excellent flow property of powder  blend.
Non aqeous wet granulation method was adopted for SR layer. Hence the mixture of drug
and  polymer  should  posses  good  flow  and  compaction  properties.  Plain  losartan
potassium exhibited angle of repose value of 37.22 ± 0.16o indicating poor flow property.
It was further supported by high Carr’s index (36.19 ± 0.14) and Hausner’s ratio (1.38 ±
0.07). Hence lubricants were added to improve the flow property of drug. The angle of
repose of all the blend was within range of 26.04 to 30.06o indicated excellent flow
property of powder  blend.
Physico-chemical evaluation of tablets:
The results of physico-chemical evaluation of bilayer matrix tablets are given in
Table  7  &  8. The  tablets  of  different  batches  of  hpmc,  eudragit  rspo  and  SSG   in
combination were found uniform with respect to thickness (3.46. to 3.64 mm). Hardness
(6.1 to 6.5 kg/cm2) and friability (0.21 to 0.41 %) were also found uniform indicating
good handling property of the prepared bilayer matrix tablets. Weight variation (1.2 to
2.1 %) and drug content (97.5 to 99.9%) were within prescribed limits. Hence tablets
containing  drug,  polymer,  binder  and  lubricants  could  be  prepared  satisfactorily  by
direct compression and non aqeous wet granulation method.
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Swelling study:
Investigation of polymer swelling and erosion is  a valuable  exercise to  better
understand  the  mechanism  of  release  and  the  relative  importance  of  participating
parameters. Bilayer matrix tablets of HPMC K 100M, Eudragit Rspo and SSG was not
found  intact  throughout  the  period  of  swelling  in  phosphate  buffer  of  pH  6.8.  The
swelling index of matrix tablets were directly proportional to the concentration of the
polymer,  as  the  polymer  concentration increases  there  was  increase  in  the  swelling
index. After 7 or 8hrs there was decrease in swelling index due to the erosion of surface
layer of matrix tablet. Formulation (f2 to f7) showed better swelling index up to 7 hr
then it starts to decline. the formulation (f1&f8) showed better swelling index up to 8 hr
then it starts to decline. On comparing the swelling index, it was observed that f6 & f7
swell  more  compare  to  other  formulation.  Table  9  &10 and  Fig  14-16 depicts  the
swelling behavior of different matrix tablets. The order of swelling of polymeric tablets
were f1>f4>f8>f2>f3>f5>f6>f7.
In-vitro release study:
A hydrophilic and hydrophobic matrix controlled release system is a dynamic
system composed of polymer-wetting, hydration and dissolution. At the same time, other
soluble  excipients  or  drug(s)  will  also  wet,  dissolve  and  diffuse  while  the  insoluble
ingredients  will  be  held  in  place  until  the  polymer  erodes  or  dissolves.  Since  the
diffusional  release  of  soluble  drug  such  as  losartan  potassium  may  primarily  be
controlled  by  the  gel  thickness  (diffusion  layer),  increasing  polymer  level  tends  to
decrease drug release.  The most common explanation of the effect of increase in the
polymer level on drug release is that, it results in the increase in the thickness of the gel
layer, which retards drug diffusion out of tablet. Given the complexity of these swellable
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matrix  systems  other  factors  such  as,  differences  in  water  penetration  rate,  water
absorption  capacity  and  swelling,  polymer  erosion  and  attrition  which  result  from
changes in the polymer content may contribute to this effect.
Dissolution studies of prepared bilayer matrix tablets were carried out in pH 1.2
for first 3 hours , pH 6.8 for 4 hour and pH 7.4 for 4 hour. The samples were analyzed
spectrophotometrically at 234 nm.
Effect of sodium starch glycolate:
Presence of super disintegrant (sodium starch glycolate) in Immediate release
layer showed faster disintegrant of the layer. This can attributed to the extent of water
uptake  and  consequently  the  strong  swelling  power  of  this  disintegrant  causing
sufficient hydrodynamic pressure to induce complete disintegration. The concentration
of ssg is directly propotional  to  release of drug. Pattern was shown in Table 11.
Effect of HPMC K100M:
The release pattern of HPMC K100M bilayer matrix tablet made with polymer
concentration of 14.7 – 19.76 % w/w were shown in Table 16-17 . It indicated that the
drug  release  was  spread  over  extended  period  of  12  hrs  with  the  variation  of  the
polymer  level.  The  dissolution  rates  from  formulation  f3  (HPMC  19.76%  w/w),   f5
(HPMC 14.7%w/w) were  67.54 and 94.82% in 12 hrs . It was evident the as the polymer
level increases the percent of drug release decreases resulting controlled release. As the
proportion of HPMC K100M was increased there was a progressive decline in the release
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rate because of the polymer gel formed was more likely to be resistance to drug diffusion
and gel erosion. The observation was in accordance with our swelling study of HPMC
K100M showed that increase in the swelling index with polymer level.
Effect of EUDRAGIT RSPO:
The  release  pattern  of  EUDRAGIT  RSPO  bilayer  matrix  tablet  made  with  polymer
concentration of 14.7 – 19.76 % w/w were shown in Table 16-17 . It indicated that the
drug  release  was  spread  over  extended  period  of  12  hrs  with  the  variation  of  the
polymer  level.  The  dissolution  rates  from  formulation  f3  (EUDRAGIT  RSPO  19.76%
w/w),  f5 (EUDRAGIT RSPO 14.7%w/w) were  67.54 and 94.82% in 12 hrs .  It  was
evident  the  as  the  polymer  level  increases  the  percent  of  drug  release  decreases
resulting controlled release. As the proportion of EUDRAGIT RSPO was increased there
was a progressive decline in the release rate because of the polymer gel formed was
more likely to be resistance to drug diffusion and gel erosion. The release of drug from
matrix tablets depends not only on the nature of the polymer but also drug polymer
ratio.
Mechanism of drug release:
           To study the release mechanism of bilayer matrix tablets, various dissolution
models were applied to the in-vitro release profiles of different formulations. The kinetic
models included zero order, first order, Higuchi and Korysmeyer-Peppas equations. As
observed from the Table  28 & 29 the values of  correlation-coefficient (r2) for all  the
formulations were high enough to evaluate the drug dissolution behavior by equation.
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The value of release exponent (n) was found to be a function of polymer used and the
physicochemical property of a drug molecule itself.  Kinetic results revealed that,  the
formulations f2 & f3  followed first order kinetics as correlation coefficient (r2) values
(0.981-0.975) are higher than that of zero order release kinetics and f1,f3,f4,f5,f6,f7,f8
formulations followed zero order rlease kinetic. The prepared hydrophilic bilayer matrix
formulations(F1,F2,F5,F6,F8)  showed  Non-Fickian  (anomalous)  case-11  trasport
release,  as  the values  of  release exponent  (n)  lies  between (1.001-1.641) with their
correlation  coefficient  (r2)  values  between  0.968-0.995,  indicating  that   diffusion,
polymer  swelling  and  erosin  were  involved  in  the  release  process.  The
formulations(F3,F4,F7)  showed  Non-Fickian  (anomalous)   trasport   release,  as  the
values  of  release  exponent  (n)  lies  between  (0.734-0.840)  with  their  correlation
coefficient (r2) values between 0.958-0.983, indicating that  diffusion, polymer swelling
were involved in the release process
Discussion for Optimization
Effect of formulation variables on Hardness
The hardness for formulations was varied from 6.1kg/cm2 to 6.5kg/ cm2 table no.
The constant and regression co efficient for R1 = + 4.00 - 0.25 * A
In this case there is significant terms.
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The linear Model for R1 was found to be Significant for hardness. The model F-value of
6.00 and the value of p is 0.0498 indicate the model is significant. From response surface
plot it was obtained that, when the concentration of SSG increase there  is decrease in
hardness, as decrease  in the concentration of ssg increase in hardness. 
Effect of formulation variables on Invitro drug release 1hr.
The Invitro drug release 1hr for formulations was varied from 9.005% - 18.14%.
The  constant  and  regression  co-efficient  for  R3=+7.49+0.71*A  -0.44*  B+1.58*C
In this case there are no significant model terms.
The linear Model for R2 was found to be not Significant for Invitro drug release 1hr. The
model F-value of 0.057 and the value of p is 0.6635 indicate the model is not significant.
The factor A has positive effect which indicates that Invitro drug release 1hr increases as
factor (SSG) increases. The factor B has negative effect which indicates that Invitro drug
release 1hr increases as factor (HPMC K100M) decreases. The factor C has positive effect
which  indicates  that  Invitro  drug  release  1hr increases  as  factor  (EUDRAGIT  RSPO)
increases.
 From response surface plot it was obtained that, when the concentration of HPMC K
100M was kept  at low level  and concentration of SSG was increased simultaneously
there is change in In vitro drug release 1hr.
Effect of formulation variables on Invitro drug release 8hr.
The Invitro drug release 8 hr for formulations was varied from 40.73% to 63.69%
The constant and regression co-efficient for R4=+49.37 - 4.96 * C
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In this case C is significant model term.
The linear Model for R3 was found to be Significant for Invitro drug release 8hr. The
model F-value of 6.95 and the value of p is 0.0387 indicate the model is significant.
The factor C has negative effect which indicates that In vitro drug release 8hr decreases
as factor (EUDRAGIT RSPO) increases. From response surface plot it was obtained that,
when the concentration of HPMC K 100M was kept at low level and concentration of SSG
was increased simultaneously there is increase in Invitro drug release 8hr. 
Effect of formulation variables on Invitro drug release 12hr.
The Invitro drug release 12hr for formulations was varied from 67.54% to 94.82%.
The constant and regression co-efficient for R4=+79.15 -0.28 *A  -6.94 * C 
In this case A , C are significant model terms.
The linear Model for R4 was found to be Significant for In vitro drug release 12hr. The
model F-value of 7.27 and the value of p is 0.0331 indicate the model is significant.
The factor A has negative effect which indicates that In vitro drug release 12hr decreases
as factor (HPMC K 15M) increases. The factor C has negative effect which indicates that
Invitro  drug  release  12hr increases  as  factor  (EUDRAGIT  RSPO)  decreases.  From
response surface plot it was obtained that, when the concentration of HPMC K 100M was
kept  at  low  level  and  concentration  of  SSG  was  increased  simultaneously  there  is
increase in In vitro drug release 12hr. 
Effect of formulation variables on Friability
The friability for formulations was varied from 0.21% to 0.41% table no.
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The constant and regression co efficient for R2 = +7.49 +0.71* A -0.44* B +1.58 * C
In this case A, B and BC are not significant terms.
The linear Model for R5 was found to be not Significant for Friability. The model F-value
of 0.57 and the value of p is 0.6635 indicate the model is not significant. The factor A has
positive  effect  which  indicates  that  friability  increase  as  factor  (SSG)  increases.  The
factor B has  negative effect which indicates that  friability increases  as factor (HPMC
K100M)  decreases.  The  factor  c  has  positive  effect  which  indicates  that  friability
increases as factor (Eudragit Rspo) increases.From response surface plot it was obtained
that, when the concentration of HPMC K 100M was kept at low level and concentration
of SSG was increased simultaneously there is steep increase in friability.
Effect of formulation variables on N  value.
The N value for formulations was varied from 0.734 to 1.641.
The  constant  and  regression  co-efficient  for  R6=+1.08  -0.039  *  A-0.23  *  C
In this case there are no significant model terms.
The linear Model for R6 was found to be not significant for N value. The model F-value of
2.61 and the value of p is 0.1678 indicate the model is not significant.
The factor A has negative effect which indicates that N value increases as factor (HPMC K
100M) decreases. The factor C has negative effect which indicates that N value increases
as factor (EUDRAGIT RSPO) decreases. 
From response surface plot it was obtained that,  when the concentration of HPMC K
100M was kept  at low level  and concentration of SSG was increased simultaneously
there is increase in N value. In the same case, when the concentration of SSG was kept at
123
DISCUSSION     
low level and concentration of HPMC K 100M increased simultaneously there is decrease
in N value.
Stability studies:
The stability studies were carried out for the optimized formula  at 40±2oC/ 75±%5 RH
for  one  month.  Table  20  shows  the  values  of  post-compressional  parameters  after
stability studies at different temperature and humidity conditions. The results indicated
that the tablets did not show any physical changes (hardness and friability) during the
study period and the drug content was found above 98% at the end of one month. This
indicates that tablets are fairly stable at storage condition.
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CONCLUSION
The following conclusions can be drawn from the results obtained.
• Preformualtion  studies  on  losartan  potassium corroborate  with  the  reported
            literature limits. 
• The adopted method yielded uniform and reproducible bilayer matrix tablets       
            with all the polymers used.
• The hardness, friability, weight variation, drug content, swelling index and in      
            vitro release were uniform and reproducible.
• The swelling index of HPMC K100M bilayer matrix tablets was studied
among  the  formulation.
• The  release  was  inversely  proportional  to  the  polymer  concentration
irrespective of the polymer used.
• The release profile of  bilayer matrix tablets containing 13.27% w/w of Hpmc
K100m And Eudragit Rspo (F5) which has given 94.82% release .
• The  release  rate  of  bilayer  matrix  tablets  containing  19.47%  w/w  of  Hpmc
K100m And  Eudragit Rspo (F3) which has given 67.54% release. Hence as the
polymer ratio increase drug release will decline.
• The mechanism of drug release was found to be non-fickian case-11 trasport.
• Selected bilayer  matrix tablets  were found to  be stable  with  respect  to  drug
content, friability, weight variation, hardness and thickness. 
• FTIR and DSC studies revealed no chemical interaction and indicating stability of
drug in tablets.
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• Hence, bilayer matrix tablets containing Hpmc k 100m, Eudragit rspo, Ssg (f5) of
losartan potassium showed promising results.
• Optimized formulation exhibited in-vitro drug release rate as per USP. 
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8. SUMMARY
The use of hydrophilic matrices has become extremely popular in controlling the release
rate of drugs from solid dosage forms. These systems are attractive from an economic as
well as process development view point.
 Losartan  potassium,  an  oral  antihypertensive  agent  used  in  the  treatment  of
hypertension.  The  short  biological  half-life  (about  2  -  2.5  hrs)  and  frequency  of
administration makes losartan potassium an ideal candidate for oral controlled release.
 Chapter 1 deals with introduction on oral drug delivery system,  combination therapy
for treatment of multiple diseases, Potential Reason for Considering the Double-layer
Dosage Form, Some novel bilayer and trilayer tablet devices, Bilayer problems , Bi-Layer
tablets: Quality and GMP-requirement, Sustained Release Drug Delivery Systems. 
The  objective  of  the  study  was  to  formulate  and  evaluate  bilayer  matrix  tablets  of
losartan potassium employing Ssg ,Eudragit Rspo and Hpmc K100m as stated in chapter
2. 
A detailed review of literature on bilayer matrix formulations and evaluations of pure
drug  losartan  potassium,  excipients  like  sodium  starch  glycolate,  Eudragit  Rspo  and
Hpmc  K100 was collected by  referring  different  journals,  books  and is  presented in
chapter 3. 
Methodology  used  in  the  preformulation  of  losartan  potassium,  formulation  and
evaluation  of  bilayer  matrix  tablets  is  described  in  chapter  4.  Drug,  polymers  and
reagents  were  procured  from  different  sources.  Methodology  on  formulation  and
evaluation of bilayer matrix tablets was adopted from reported methods. Formulation
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variables include nature and concentration of polymers, and their combinations. Bilayer
matrix tablets are characterized for physico-chemical properties,  in vitro release and
stability. Experiments were conducted in triplicate. 
Chapter  5  contains  the  results  obtained  from  formulation  and  evaluation  of  bilayer
matrix  tablets  and the  data  are  presented in  Tables  and Figures.  The  discussion on
results obtained during the present study is given in chapter 6.
 Preformulation  studies  on  losartan  potassium  were  in  agreement  with  reported
literature. The method adopted in the preparation yielded tablets with uniform weight,
thickness, hardness; friability and drug content was found within the prescribed limits.
Modulation of drug release was effected by nature and concentration of polymers. The
swelling index of Hpmc k 100m, Eudragit rspo bilayer matrix tablets was compared with
other  formulation(f1-f8).  Among  all  the  formulations,  f5  were  given  complete  and
sustained drug release over a period of 12 hrs.
 All these9(f1-f8) bilayer matrix tablets exhibited non-fickianan (anomalous)  and Non-
Fickian  case-II trasport diffusion. Among all these formulations f5 was selected as best
formulation because polymer in low concentration, which showed better sustained drug
release over12 hr,  as  compared to  other selected  formulation.  Bilayer  matrix  tablets
were found to be stable with respect to drug content,  friability, hardness and weight
variation during the stability study period. FT-IR and DSC study revealed no interaction
between drug and excipients used. 
Conclusion was drawn from the discussion and placed in chapter 7. The present study
conclusively proved that controlled release bilayer matrix tablets of losartan potassium
can  be  efficiently  prepared  by  using  HPMC  K100M,eudragit  rspo  and  ssg  their
combinations.  And  the  prepared  tablets  gave  the  promising  results  for  once  a  day
administration of losartan potassium. 
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Vancouver style was followed to write the references quoted in the study and is listed in
the chapter of bibliography
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